Tag

Tagged: Medical Technology

Sponsored
8 hours ago

Management Without Knowledge

HealthPad
Directory:
Medical Technology
Tags:
commentary
corporate culture
leadership
management
MBA
Medical Technology
scientific management

  • Management governs almost everything - without meeting the standards of a science or a profession
  • Its authority rests on rhetoric, metrics, and moralised abstractions, not falsifiable knowledge
  • Business schools and MBAs institutionalise legitimacy while insulating theory from failure
  • Healthcare exposes management as an epistemic stress test it repeatedly fails
  • Management endures not because it explains or predicts, but because it legitimates power

Management Without Knowledge

Management today exercises significant authority. It governs hospitals, universities, health systems, multinational corporations, NGOs, and public administrations. It structures how work is organised, how performance is measured, how success and failure are defined, and how resources are allocated. Few domains of social life remain untouched by managerial logic.

So, a pair of questions, addressed directly to those who lead: when was the last time you were asked to defend a major management intervention with the same evidential standard demanded of a clinical decision, a legal argument, or a capital investment? And if your dashboards and operating models are “evidence-based,” what would it look like to falsify them - what result would make you stop doing what you are doing?

Yet despite this reach, management is a fragile form of knowledge. It is not a science in any conventional sense, not a profession in the way medicine or law are professions, and increasingly not a coherent body of cumulative understanding. What, then, is the real basis of managerial authority: predictive power - or institutional permission? And how often do we mistake measurement for understanding, and control for competence?

This tension - between expansive authority and weak epistemic foundations - defines the managerial myth. Management presents itself as neutral, technical, and evidence-based, while in practice relying on rhetorical frameworks, stylised models, and moralised abstractions that resist empirical scrutiny. Its influence does not derive from demonstrable explanatory or predictive power, but from its role as a legitimating language for control.

Healthcare offers a vantage point. Here, managerial knowledge confronts complex systems, high stakes, and entrenched professional expertise. Failures cannot easily be disguised as “learning experiences,” and abstract models collide with embodied clinical judgment. If management were scientific, healthcare would be the domain in which its value became most evident. Instead, it is often where its limitations are most exposed. In a system where harm is measurable and delay is lethal, what are we optimising - and who gets to decide when the “model” is wrong?
 
In this Commentary

This Commentary argues that modern management wields significant authority while resting on fragile epistemic foundations. Neither a science nor a profession, management functions primarily as an ideological language that legitimates control while evading falsification and accountability. Using healthcare as a stress test, the Commentary shows how managerial abstractions displace professional judgment, obscure trade-offs, and exercise power without knowledge robust enough to justify it.
 
The Early Promise of Scientific Management

The ambition to render management scientific was not always illusory. Early twentieth-century management thinkers sought to align organisational control with empirical observation and rational method. Frederick Taylor’s time-and-motion studies, for all their moral and political problems, were animated by a belief that systematic measurement could improve organisational performance. Later developments in systems theory, operations research, and cybernetics similarly aspired to formal rigour.

These efforts shared a core assumption: that organisations could be understood as objects of systematic inquiry, governed by generalisable principles, and improved through evidence-based intervention. Management knowledge, on this view, would be cumulative. Findings would be tested, refined, discarded, or integrated into a growing body of understanding.
Hydrocephalus is shifting from a device market to a multi-billion-dollar neurotechnology platform opportunity. In the new episode of HealthPadTalks, Hydrocephalus 2.0: Neurotech’s Next Billion-Dollar Platform we explore the move from failure-prone shunts to adaptive, closed-loop systems integrating smart sensing, biologics, connectivity, and minimally invasive access. The companies that own the system architecture and data loop will define the next era of neurotech. 
What followed was something different. Rather than converging on shared standards of evidence and falsification, management knowledge fragmented into competing schools, frameworks, and fashions. The field became characterised less by cumulative progress than by periodic waves of enthusiasm: each new concept promising to solve problems that the last had failed to address. Total Quality Management, Business Process Reengineering, Six Sigma, Design Thinking - each arrived with confident claims, limited evidence, and a short half-life.

Crucially, these failures did not provoke epistemic crisis. Unlike in the natural sciences, where persistent failure would call foundational assumptions into question, management theory proved resilient. Concepts faded not because they were falsified, but because they were displaced by newer narratives better suited to changing organisational anxieties.
 
The MBA and the Abandonment of Falsifiability

The institutional heart of this transformation lies in the rise of the MBA. Business schools became the primary sites through which management knowledge was produced, standardised, and disseminated. Yet the MBA did not evolve as a research training programme. It emerged as a credentialing mechanism, designed to signal competence, authority, and readiness to lead.

MBA pedagogy relies on case studies, stylised models, and retrospective success stories. These tools are pedagogically effective and rhetorically powerful, but epistemically weak. Case narratives cannot establish causal claims. Stylised models depend on simplifying assumptions rarely examined in practice. Success stories are subject to survivorship bias and retrospective rationalisation.

Most importantly, MBA knowledge is structured to avoid falsification. When an organisation succeeds, its leaders are credited with effective management. When it fails, the explanation is almost always contextual: poor execution, cultural resistance, insufficient buy-in, or unforeseen external shocks. The underlying theories remain intact. There is no clear mechanism by which management ideas can be disproven.

This is not an accidental flaw. It is a structural feature of a field that prioritises legitimacy and applicability over truth claims. Management knowledge must be adaptable, reassuring, and broadly resonant. Rigid adherence to empirical standards would undermine its usefulness as a general-purpose language of authority.
 
From Science to Ideology

As its scientific pretensions weakened, management theory assumed a different role. It became ideological - not in the sense of false consciousness, but as a system of meaning that legitimates power relations while presenting itself as neutral and technical.

Management discourse is saturated with moral vocabulary: efficiency, excellence, leadership, innovation, resilience. These terms are rarely defined with precision, yet they carry strong normative force. To oppose them is to appear irrational or irresponsible. Who could be against efficiency, or excellence, or innovation?
You might also like to listen to:
 
In this way, management language performs a political function. It frames organisational decisions as technical necessities rather than contested choices. Downsizing becomes “rightsizing.” Cost-cutting becomes “optimisation.” Centralisation becomes “strategic alignment.” The language obscures trade-offs and suppresses alternative value systems.

This ideological function helps explain why management theory remains influential despite weak empirical performance. Its authority does not depend on predictive accuracy, but on its capacity to render decisions intelligible and defensible within elite institutional settings.
Why Management Is Not a Profession

Management also fails to meet the criteria of a profession. Professions are defined by specialised knowledge, formalised training, enforceable standards, and mechanisms of accountability. Medicine, law, and engineering all involve bodies of knowledge that practitioners must master, ethical codes they must uphold, and institutions that can sanction malpractice.

Management lacks these features. There is no agreed-upon core body of knowledge that managers must possess, no standardised pathway to competence, and no enforceable ethical code specific to managerial practice. Anyone can be a manager; success is typically inferred retrospectively from outcomes rather than evaluated prospectively against defined standards.

This absence of professional accountability has consequences. When management decisions cause harm - the loss of value, organisational collapse, systemic inefficiency, or degraded care quality - responsibility is diffuse. Failures are attributed to complexity, uncertainty, bad luck or exogenous forces. Rarely are they framed as professional malpractice.

In healthcare, this asymmetry becomes more striking. Clinicians are subject to rigorous training, licensing, peer review, and legal liability. Managers who shape the conditions under which clinicians work face weaker forms of scrutiny, despite wielding substantial influence over outcomes.
 
Healthcare as an Epistemic Stress Test

Healthcare and its adjacent life-science industries impose unusually high demands on knowledge. Decisions are time-sensitive and morally charged, with consequences that bear directly on human wellbeing. Clinical, operational, and R&D processes are complex, nonlinear, and only partially observable. Outcomes emerge from the interaction of biological variability, social determinants, professional judgement, organisational incentives, and institutional constraints - factors that resist reduction to stable inputs and outputs.

These characteristics make the broader healthcare ecosystem - providers and payers, regulators and supply chains, as well as pharma, biotech, MedTech, and other life-science organisations - a stringent test case for management theory. If abstract managerial frameworks reliably enhanced organisational performance, their effects should be most visible in domains where uncertainty is high, stakes are existential, and learning is costly. Instead, this ecosystem repeatedly exposes the limits of managerial rationality when applied to complex human systems.

Performance indicators frequently fail to capture what matters clinically or scientifically. Efficiency metrics can distort priorities, privileging throughput over care quality, safety, or relational work; in R&D settings, they can over-optimise for tractable milestones rather than translational value. Standardisation initiatives, while framed as best practice, may erode professional discretion and undermine context-sensitive decision-making. Organisational reforms justified through managerial language often generate unintended - and sometimes counterproductive – consequences because they treat contested, value-laden judgements as if they were engineering parameters.

Crucially, these failures are rarely interpreted as evidence of deficiencies in management knowledge. Responsibility is displaced onto the domain: healthcare is deemed too complex, too culturally resistant, too regulated, or insufficiently mature in its managerial capabilities; life-science organisations are said to be uniquely uncertain, unusually risk-averse, or distorted by incentives. In this way, management theory remains insulated from falsification. When it succeeds, success is attributed to good management; when it fails, the problem is said to lie with healthcare (or with pharma, biotech, MedTech, and their institutional environments). The field thus functions not only as a site of application, but as an epistemic stress test that management theory persistently fails - without being forced to reckon with that failure.
 
The Displacement of Professional Judgment

One of the most consequential effects of managerial expansion across healthcare - and the wider life-science ecosystem that shapes it - is the displacement of professional judgement. Clinical expertise is increasingly subordinated to protocols, targets, and performance dashboards designed at a distance from the point of care. Analogous dynamics appear upstream in pharma, biotech, and MedTech: scientific and engineering judgement is channelled through stage gates, KPIs, and compliance templates that often privilege procedural certainty over situated expertise.

This shift is typically justified as a move toward objectivity and accountability. Yet the metrics that enable it are themselves products of managerial abstraction. They privilege what can be counted over what is consequential, translating complex clinical or scientific realities into simplified indicators optimised for monitoring, comparability, and reporting. What is lost is not only nuance, but the legitimacy of tacit knowledge - those context-sensitive assessments that cannot be fully specified in advance.
The result is a form of epistemic inversion. Those with the least direct knowledge of clinical practice (or of experimental and translational work) can acquire authority through fluency in managerial language, while those with the most expertise are required to justify decisions in terms they did not define. Professional reasoning becomes legible only once it is translated into the categories of the dashboard.
You might also:

The Talent Delusion

 
This dynamic does not eliminate discretion; it redistributes it. Decisions are still made, but the criteria by which they are evaluated shift from professional standards to managerial ones. The operative question is no longer “Was this good care?” - or “Was this the right scientific call under uncertainty?” - but “Did this meet the target?” In that shift, judgement is not removed; it is displaced, and its accountability is re-anchored to what the system can measure rather than to what the domain most needs to know.
 
Management Theory’s Circular Economy

The durability of management theory is sustained less by cumulative explanatory power than by a self-reinforcing citation economy. A small set of elite journals disproportionately cite one another, reproducing shared assumptions, preferred methods, and accepted problem framings. While critical perspectives are periodically acknowledged, they are rarely permitted to alter the field’s core categories or evaluative standards. Recognition substitutes for incorporation.

Empirical research within this ecosystem frequently relies on self-reported measures, cross-sectional designs, and statistical techniques that confer the appearance of rigour without resolving underlying conceptual ambiguities. Findings are typically incremental, context-bound, and weakly replicable. Yet through repeated citation, these results are recontextualised as building blocks of a cumulative literature. Methodological conformity enables publication; publication generates citations; citations are then taken as evidence of theoretical solidity. What circulates is not validated knowledge, but mutual reinforcement.

This epistemic circularity is institutionally stabilised by business school incentive structures. Faculty advancement, funding, and status depend on publication within the same narrow journal hierarchy that defines legitimate knowledge. Research that questions foundational assumptions - rather than extending them - faces elevated barriers to entry. Critique is permitted insofar as it is framed in the field’s authorised vocabularies and methodologies. Challenges that would disrupt the circulation itself are filtered out, ensuring that the system reproduces its own criteria of success.
 
A Genealogical Perspective

Explaining how management came to occupy its current position of authority requires a genealogical approach. Rather than evaluating management theories in terms of truth or falsity, genealogy asks how they emerged, what historical problems they were intended to address, and which interests they came to organise and stabilise. The focus shifts from epistemic validity to conditions of possibility.

Viewed genealogically, management knowledge appears less as a cumulative science and more as a succession of discursive formations shaped by changing social, economic, and organisational conditions. As enterprises expanded in scale and complexity, older forms of coordination - personal supervision, craft knowledge, informal norms - proved insufficient. New vocabularies were required to render organisations legible, comparable, and governable. Management theory supplied these vocabularies, translating heterogeneous practices into abstract categories such as performance, efficiency, leadership, and control.

This perspective is indebted, in part, to Michel Foucault’s analysis of the entanglement of knowledge and power. Management discourse does not just describe organisational realities; it actively constitutes the objects it claims to analyse, defining what counts as a problem, what can be measured, and what forms of intervention are deemed legitimate. In doing so, it shapes both how organisations are understood and how they are governed.

Seen in this light, the central puzzle is not why management theory falls short of conventional scientific standards, but why such shortcomings have had little effect on its institutional authority. Its durability lies in its practical function: management theory operates less as an explanatory body of knowledge than as a technology of governance. Its value is measured not by its truth claims, but by its capacity to structure action, allocate responsibility, and render organisational life amenable to intervention.
 
Why Critique Has Not Transformed Management

Management has been criticised for decades - by labour scholars, organisational sociologists, critical theorists, and practitioners themselves. Yet these critiques have rarely shifted the centre of gravity of mainstream practice.

One reason is that management theory is highly assimilative. Critical ideas are not so much rejected as domesticated: they are absorbed, rebranded, and returned as tools. Reflexivity is reframed as leadership development. Power is translated into stakeholder management. Resistance is recoded as change management. In this process, critique survives as language but loses its edge as diagnosis - its political and structural implications are converted into managerial technique.

A second reason is that management’s authority is not primarily epistemic. It does not depend on being true so much as being usable - especially by those with the capacity to act. If managerial discourse helps organisations justify decisions, coordinate action, discipline uncertainty, and perform legitimacy for regulators, investors, and publics, then its weaknesses as knowledge are tolerable. In other words, critique struggles to transform management because management is organised less as a truth-seeking enterprise than as a practical and justificatory technology - one that can incorporate criticism without conceding power.
 
The Cost of Unscientific Authority

The consequences of this arrangement are no longer abstract. As managerial logic extends into domains once governed by professional norms, the costs of unscientific authority become increasingly legible - and increasingly hard to dismiss as implementation failure.

In healthcare, these costs show up as misaligned incentives, burnout, erosion of trust, and the quiet displacement of clinical judgement by targets, dashboards, and procedural compliance. They also surface in healthcare-adjacent organisations - commissioners, regulators, insurers, digital health firms, and suppliers - where “what counts” is often shaped upstream through metrics, contracts, and reporting regimes that travel faster than evidence. The result is a system that can look controlled on paper while becoming less adaptive on the ward, in the clinic, and across the care pathways.

More broadly, unscientific authority produces organisational fragility: repeated cycles of reform and disappointment; constant restructures that generate motion without learning; and a persistent gap between managerial rhetoric (“transformation”, “efficiency”, “quality”) and lived experience. When success is defined through proxies that are only loosely coupled to real outcomes, organisations optimise what is measurable and narratable, not necessarily what is true or beneficial.

These outcomes are not accidents. They are predictable consequences of a regime in which management knowledge is insulated from rigorous evaluation, largely unaccountable as a profession, and legitimised by its association with science rather than by the disciplined practice of it. Under those conditions, managerial authority can expand even when its claims fail - because it is rewarded for coherence, control, and legitimacy, not for accuracy.
 
Reframing the Question

The point is not to romanticise pre-managerial forms of organisation or to deny the need for coordination and administration. Large, complex systems require structures of management. The question is on what epistemic and ethical grounds these structures operate.

If management is not a science, it should stop claiming the authority of one. If it is not a profession, it should not displace those that are. And if its knowledge claims cannot withstand empirical scrutiny, they should be treated as provisional frameworks rather than universal truths.

Healthcare, with its moral urgency and epistemic complexity, makes these questions impossible to ignore. It reveals what management discourse often conceals: that governing through abstraction is a choice, not a necessity, and that the legitimacy of that choice depends on standards management has largely abandoned.
 
Takeaways

Management today governs through a paradox: it wields significant power while resting on fragile knowledge claims. It borrows the prestige of science without accepting the disciplines that make science real - clear hypotheses, the possibility of being wrong, and the willingness to stop when the evidence turns - while displacing professional judgement without assuming professional responsibility. In doing so it converts complex care, work, and risk into legible proxies that travel well in board packs but fracture at the bedside. Naming this is not a call for denunciation or nostalgia; it is a strategic demand for epistemic honesty. If leaders want their interventions to carry the authority of evidence, they should be prepared to state, in advance, what will falsify them; if they want dashboards to substitute for judgement, they should be able to show the outcomes they improve and the harms they do not. We should treat management for what it has become - a dominant coordinating language of modern institutions - and then insist it earns its reach through transparent evaluation, clear accountability, and measurable effects on real outcomes. The danger is not management per se, but the illusion that it is a science or a profession when it is neither; healthcare has already paid the price of that illusion, and whether we learn from it is the choice now.
view in full page
2 weeks ago

The Talent Delusion

HealthPad
Directory:
Medical Technology
Tags:
commentary
leadership
Medical Technology
meritocracy
performance
talent

  • Markets do not discover talent; they manufacture it after success has already occurred
  • What looks like ability is usually accumulated position, timing, and sponsorship
  • Hiring, promotion, and performance metrics legitimise inequality more than they predict value
  • “Talent” functions as an ideology, turning structural advantage into moral entitlement
  • So, the real question isn’t “how do we find more talent?” - it’s “what do we fail to fix when we associate outcomes with ‘talent’?”

The Talent Delusion
- Why Markets Reward Position, Not Ability -

Do we mistake position for talent? If we do, it isn’t a philosophical error - it’s a strategic one.

Labour markets like to market themselves as merit machines: compete for ability, reward performance, elevate the exceptional. In that story, inequality is an audit trail - proof that winners earned their place. It is comforting because it turns messy outcomes into clean explanations. And it becomes operational doctrine: in hiring, pay, promotion, investment, and policy. Assumed, not tested.

But once you manage as if talent is a reliable signal, you start compounding a specific kind of error: confusing advantage with aptitude. The “merit” story stops being neutral. It becomes a risk multiplier.

The deeper problem is not that meritocracy is poorly executed. It is that “talent” is not a stable object markets can consistently identify, measure, and reward. What organisations call talent is often a retrospective label - applied after outcomes are visible - to explain and legitimise who got money, status, and authority. Success produces the label; the label explains the success. Circular, but effective.

In practice, what gets rewarded is positional advantage: early access to opportunity, institutional prestige, proximity to decision-makers, sponsorship by incumbents, favourable timing, and the compounding effect of being selected once and therefore selected again. Over time, these advantages become indistinguishable from “ability” on CVs, in performance reviews, and inside leadership narratives.

Markets do not just misallocate talent. They manufacture it - by converting structural advantage into a personal attribute. Talent is not discovered; it is named.

That distinction matters because it changes the solution set. If inequality is framed as a measurement problem, the response is technical: better assessments, broader pipelines, sharper metrics, improved DEI. Useful, but limited - they refine the story while preserving its function.

If talent is largely a post-hoc fiction, the implications cut deeper. Many practices used to justify pay gaps, succession decisions, leadership concentration, and cultural hierarchy are not evidence-based mechanisms for value creation. They are rationalisations of position and power.

For boards, executives, and investors, seeing this clearly is not academic - it is strategic. It forces a harder question than “How do we find better talent?”: What if the concept itself is obscuring what drives success?
 
In this Commentary

This Commentary challenges the core assumption of modern meritocracy: that markets identify and reward ability. It argues that ‘talent’ is not a measurable, portable quality but a retrospective story used to legitimise unequal outcomes. Drawing on economic and organisational research, the Commentary shows how position, timing, and institutional and social advantage are converted into moralised narratives of merit - and why this matters for leaders, boards, and capital allocation.
 
Beyond Meritocracy: Why Talent Cannot Do the Work Assigned to It

Most critiques of meritocracy accept the existence of talent while questioning whether it is rewarded. Inequalities in education, discrimination in hiring, and inherited advantage are said to distort otherwise legitimate selection processes. The underlying premise remains that individuals possess stable, generalisable abilities, and that labour markets can, in principle, identify and compensate these differences.

We reject this premise and suggest that talent fails as a market concept along three dimensions: observability, transportability, and predictiveness.

90% of drug candidates die before they ever matter - the “Valley of Death.” Phase-0: The Trial Before the Failure, the new episode of HealthPadTalks, goes to the failure point most pipelines avoid: Phase-0. We explore how microdosing, ultra-sensitive measurement, and AI-designed molecules turn early clinical insight into human truth - so teams make smarter calls, protect patients, and stop burning capital. 
Talent Is Not Observable
Labour markets cannot directly observe ability. What they observe are outputs - sales figures, publications, leadership evaluations, performance ratings - that are contingent on context and on imperfect performance measurement. Organisational sociology and personnel economics have long shown that individual performance is sensitive to team composition, managerial practices, task allocation and internal job design/assignment, resource availability and environmental constraint.

Empirical evidence confirms this instability. Meta-analyses of performance appraisal systems demonstrate significant measurement error and low inter-rater reliability, even within the same organisation. When results change depending on the situation, it is no longer credible to claim they are driven by some fixed, “built-in” trait of the individuals involved.

Talent Is Not Transportable
Labour markets assume that ability travels with individuals - that a high performer in one organisation will perform similarly in another. Yet studies of worker mobility show large performance regressions following job transitions, particularly when individuals move between firms with different structures or cultures.

The “portable skills” narrative obscures the extent to which performance is system dependent. What appears as individual brilliance often reflects complementary assets: strong teams, established routines, reputational spillovers, and institutional support. Remove these, and “talent” frequently evaporates.

Talent Is Not Predictive
Perhaps most damaging to the talent narrative is the weak predictive power of selection systems. Decades of research on hiring methods show that commonly used tools - unstructured interviews, résumé screening, reference checks - have low validity for predicting future job performance.

Even structured interviews and cognitive tests, often cited as best practice, offer only modest predictive power and deteriorate over longer horizons. Algorithmic hiring tools, despite their sophistication, largely optimise historical proxies such as education, tenure, and prior employers, inheriting the biases embedded in past decisions.

In short, labour markets lack reliable mechanisms for identifying future excellence. The belief that firms can detect talent ex ante is sustained more by confidence than by evidence.
  
The Machinery of Merit: How Organisations Manufacture Talent

If talent is not “found,” why does it feel so real? Because organisations do not simply spot ability - they create the appearance of it. Through hiring, promotions, titles, pay, and praise, they turn early advantage into recognised status, and then present that status as proof of underlying ability.
You might also like to listen to:
 
Hiring Systems and Positional Sorting
Hiring decisions rarely operate on raw assessments of capability. Instead, they rely on proxies that signal prior access to opportunity: elite education, prestigious employers, uninterrupted career trajectories. These signals correlate weakly with underlying ability but strongly with socioeconomic background.

Algorithmic hiring systems amplify this effect. By training on historical data, they optimise for characteristics associated with past success - success that reflected earlier selection biases. As a result, algorithmic screening often increases efficiency while entrenching inequality, presenting positional advantage as objective assessment.
Selection thus becomes self-validating. Candidates chosen through these processes are labelled “high quality” by virtue of having been chosen. The act of selection itself becomes evidence of talent.

Performance Metrics and Cumulative Advantage
Performance metrics are commonly treated as neutral indicators of value creation. In practice, they capture what is measurable, not necessarily what is valuable. Research in organisational behaviour shows that metrics reward visibility, alignment with managerial priorities, and role design as much as effort or skill.

Early success - often driven by luck or favourable assignment - generates reputational capital that improves access to resources and high-impact projects. This dynamic, described by Merton (1968) as the “Matthew Effect”, produces cumulative advantage: small initial differences compound into large disparities over time.

Performance metrics, then, are often less a neutral measure of “ability” and more a mechanism that sorts people into winners and losers. What we later call “talent” is frequently not the original driver of success, but the story we tell after the system has rewarded some and sidelined others.
 
Promotion and the Aesthetics of Potential

Promotion decisions often hinge less on measurable output than on judgments of “potential”, “leadership presence”, and “cultural fit”. These signals are inherently subjective - and, crucially, relational: they are formed and validated through visibility, advocacy, and internal networks. As a result, sponsorship by senior figures can be a decisive driver of advancement, predicting progression even after accounting for objective performance.

Once promoted, individuals are retrospectively reclassified as ‘talented’. Those passed over are redefined as less capable, even when performance differences are marginal. Thus, promotion systems do not reveal talent; they confer legitimacy on those already favoured by organisational power structures.
 
Talent as Ideology: The Moral Work It Performs

If “talent” is empirically fragile, why does it carry such authority? Because it does moral work. It converts unequal outcomes into deserved rewards.

Labour markets generate hierarchy under uncertainty: individual contribution is hard to isolate, and outcomes are shaped by timing, luck, networks, and institutional context. When causality is noisy, inequality still needs a story. Talent supplies it - retroactively translating contingent advantage into personal merit and recasting structural and stochastic forces as individual virtue.

This is the same legitimising move as “efficiency” in monopoly debates or “deservingness” in welfare policy. Talent naturalises hierarchy, makes inequality feel fair, and does it in the language of neutrality and progress.

Its grip does not depend on truth; it depends on usefulness. For organisations, it depoliticises selection and reward. For elites, it reframes privilege as achievement.

You see this most clearly at the point of selection. Hiring - human or algorithmic - must turn messy signals into crisp decisions. “Talent” is the compression algorithm. AI screening often intensifies, rather than fixes, the problem: correlations become “predictions of quality”, regularities get rebranded as latent traits, and historically contingent patterns acquire a sheen of objectivity. The result is not a more accurate measure of talent - it is a more authoritative story about it.
 
Moving Past the Meritocracy Critique

Much contemporary criticism of meritocracy focuses on its moral and social consequences: arrogance among those who succeed, humiliation among those who do not, and the erosion of shared civic bonds. Thinkers such as Michael Sandel argue that meritocratic narratives obscure the role of luck while encouraging hubris among “winners” and resentment among “losers.”
We build on this critique but depart from it in a crucial respect. The central problem is not that meritocracy produces objectionable attitudes or corrosive social dynamics. It is that merit - when operationalised as talent - lacks ontological coherence. Even a procedurally fair system could not reliably identify talent, because there is no stable, context-independent property to be identified.
You might also like to listen to:

Diversification Is a Trap
This shift in framing changes what reform looks like. Calls for fairer hiring practices, broader access, or more sophisticated metrics assume that talent exists as a latent attribute awaiting better discovery. However, if talent is a retrospective construct - assembled after the fact from outcomes and institutional validation - then such reforms address surface inequities while leaving the underlying fiction intact. They improve the optics of selection without resolving its conceptual foundations.
 
A Global, Structural Phenomenon

The dynamics described here are not culturally idiosyncratic nor confined to any single institutional setting. Across advanced economies - liberal, coordinated, and state-led alike - the same patterns recur, credential inflation, elite reproduction, and retrospective narratives of talent. These dynamics surface not only in private firms but also in public institutions and academia, spanning contexts with different regulatory regimes, welfare systems, and professional cultures.

Healthcare and life sciences organisations offer a clear illustration. In pharmaceutical R&D, academic medicine, MedTechs, and biotech start-ups, hiring and promotion are governed by credentialing, peer review, and evidence-based evaluation. Yet advancement is routinely justified through post hoc attributions of “scientific talent,” “clinical judgement,” or “innovative capacity,” even where outcomes depend on team composition, institutional infrastructure, regulatory timing, and access to capital or patient populations. Success is retrospectively individualised, while failure is depersonalised or attributed to exogenous risk - reproducing hierarchy without requiring a stable or measurable account of individual contribution.

This convergence points to a structural rather than cultural explanation. Wherever labour markets allocate rewards under conditions of uncertainty, and wherever unequal outcomes demand moral and institutional justification, talent emerges as a convenient fiction. Its substantive content varies - coded as “excellence,” “leadership,” or “translational impact” - but its function remains constant. Talent provides a portable language through which contingent advantage is stabilised, hierarchy rendered legitimate, and selection practices insulated from political contestation.

Seen in this light, the global spread of talent discourse is not evidence of its empirical validity, but of its adaptability. It travels easily across borders and sectors because it resolves a shared problem faced by modern healthcare and life sciences systems: how to organise high-stakes expertise, distribute prestige and reward, and sustain inequality at scale while preserving the appearance of scientific and moral fairness.
 
What Would Replace Talent?

Rejecting talent does not entail rejecting evaluation, differentiation, or standards. Organisations must still allocate roles, responsibilities, and rewards. The challenge is not whether to evaluate, but how to do so without relying on fictive moral narratives that repackage uncertainty and contingency as individual virtue.

From Individual Excellence to Systemic Contribution
One alternative is to shift evaluation away from individuals and toward systems of work. A substantial body of organisational research shows that outcomes are better explained by collective processes - coordination, learning, communication, and resilience - than by stable individual traits. As demonstrated in Leading Teams, team design and organisational context account for more variance in performance than the personal qualities of team members. Rewarding systemic contribution reframes performance as emergent rather than intrinsic, recognising that value is produced through interaction, infrastructure, and institutional support rather than isolated excellence.

From Selection to Allocation
A second shift is from selection to allocation. Rather than claiming to identify the “best” candidates, ex ante, organisations can treat hiring and promotion as provisional placements under uncertainty. Structured experimentation - through role rotation, probationary assignments, and feedback-driven reassignment - acknowledges that fit and effectiveness are discovered over time. This approach replaces the fiction of predictive certainty with mechanisms for learning and adjustment, making error correction a feature of the system rather than a moral failure of individuals.

From Moral Narratives to Institutional Accountability
Finally, inequality itself should be justified institutionally rather than morally. Pay differentials, authority, and hierarchy should be defended in terms of functional necessity - coordination costs, responsibility, or scarcity - rather than superior worth. This shift would require greater transparency about how rewards are set and a willingness to revise structures that fail to deliver collective value. Inequality becomes a contingent organisational choice, open to evaluation and reform, rather than a naturalised outcome of individual merit.

Taken together, these shifts do not abolish judgement; they relocate it. Evaluation moves from character to contribution, from prediction to learning, and from moral status to institutional design.
 
Takeaways

We do confuse title with talent - and this confusion is not harmless; it is strategic risk. “Markets reward talent” works as a comforting story: it reassures winners, disciplines everyone else, and makes inequality feel deserved. But talent, as markets use it, cannot bear that load: it is not cleanly observable, reliably portable, or consistently predictive. More often it is assembled after the fact - manufactured through visibility, sponsorship, and narrative control - then retrofitted into a morality tale called “merit”. So, when markets do not reward “true” talent, that is not a glitch in a fair system; it is the system doing what it is built to do: allocate under uncertainty while supplying moral cover. Dropping the fiction would not erase hierarchy - it would remove inequality’s moral alibi, forcing disparities to be justified by function, responsibility, risk, and collective value rather than implied virtue. That is a harder argument. It is also the accountable one - and it is why this is the confusion worth confronting.
view in full page
1 month, 3 weeks ago

In Defence of the One-Trick Pony

HealthPad
Directory:
Medical Technology
Tags:
AI
commentary
digitalisation
Medical Technology
MedTech

        

  • Why “one-trick pony” is a silencing critique, not a serious argument
  • How digital, AI, and platform dynamics have shifted where advantage is created
  • Why strategic breadth now delays learning rather than reducing risk
  • The hidden danger of legacy playbooks in non-linear systems
  • Why focus, conviction, and compounding depth matter more than balance
 
In Defence of the One-Trick Pony

Few phrases shut down a strategic discussion as effectively as “one-trick pony.” It is rarely spoken aloud. More often, it surfaces obliquely and anonymously - relayed as a signal of experience and restraint. We see the bigger picture. We understand complexity. We’ve lived through enough cycles not to be distracted by the latest enthusiasm.

It is, above all, the language of reassurance. Reassurance to peers that prudence still governs decisions. To boards that breadth implies maturity. To investors that leverage will remain serviceable, integrations controllable, and earnings predictable. And perhaps most importantly, reassurance to oneself that caution remains a virtue.

HealthPad Commentaries are not written to reassure. They are written to provoke reflection. As they have focused on digitalisation, AI, and platform dynamics reshaping healthcare and life sciences, the one-trick pony refrain has surfaced as critique. The implication is that technology-led strategies are reductive; that healthcare, life sciences, and MedTech are different. Their biology is complex. Their regulation is heavy. Their ethics demand care. Their balance sheets are tightly managed. A broader, more measured approach is therefore assumed to be wiser.

All of this is true. And all of it is increasingly beside the point.

Nowhere is this clearer than in MedTech. Over three decades, most legacy MedTech companies have converged on a single operating logic: manufacturing-led scale reinforced by M&A roll-ups. Operationally excellent, regulatorily competent, and financially disciplined - optimised for margin protection, debt servicing, and integration synergies. Yet strategically hollowed out. As value has migrated from devices toward data, software, and services, incumbents have remained structurally optimised for producing hardware and smoothing earnings, not for building learning systems or compounding insight. As a result, they are among the most exposed to digital and AI disruption.

The irony is that the critique of focus arrives just as strategic breadth has become one of the highest-risk choices a leadership team can make. Not because these sectors are simple - but because the technologies reshaping them are unforgiving. Platform economics do not reward optionality. They reward depth, speed of learning, and early accumulation of proprietary advantage. Diffusion, however financially prudent it appears in a quarterly cycle, is penalised over time.

In periods of technological discontinuity, being a one-trick pony is not a failure of imagination. It is an act of strategic clarity. Advantage no longer accrues to those who manage complexity best - financial, regulatory, or organisational - but to those who choose which complexity to confront first and commit to mastering it faster than everyone else.

In healthcare, life sciences, and MedTech - industries defined by regulation, capital intensity, and inertia - this runs against instinct. Yet it is these conditions that make focus essential. When erosion begins slowly and then accelerates, the organisations that feel safest - diversified, hedged, financially “balanced” - are often the most exposed.
 
This Commentary

This Commentary responds to a familiar but rarely examined critique: that sustained attention to, emphasis on, and preoccupation with digitalisation, AI, and platform dynamics represents a narrow or reductive view of healthcare strategy. It argues the opposite. In an era of non-linear technological change, concentration is not a weakness but a prerequisite for relevance. The Commentary challenges the comfort of strategic breadth, reframes the “one-trick pony” accusation as a political shorthand rather than a substantive argument, and makes the case that durable advantage in healthcare, life sciences, and MedTech now comes from choosing which complexity to confront first and committing deeply enough for learning and advantage to compound.
 
The Comfort of the Insult

Calling a strategy a “one-trick pony” is not an analytical critique. It is an insult - one designed less to test an idea than to end a discussion. It is rarely deployed openly, and almost never in good faith as a strategic argument. Instead, it functions as a cultural signal: this line of inquiry is naïve; seriousness requires breadth; conviction is something to be managed, not expressed.

The charge reassures colleagues and flatters its author. It affirms that leadership means juggling priorities, hedging commitment, and avoiding visible over-investment in any single direction. In healthcare, life sciences, and MedTech, this posture has been rewarded for decades - particularly among leaders who built their careers before digitalisation, AI, and platform dynamics became central sources of advantage. For many, these are not native domains but acquired literacies, and re-learning them - late, publicly, and without certainty of payoff - is neither attractive nor culturally incentivised.
New forces are reshaping MedTech. Power is shifting from hardware to AI-driven, data-rich platforms that span the full patient journey. Momentum is accelerating beyond the US and Europe into Saudi Arabia, India, and Africa. New markets, new rules, new rivals. The next MedTech winners won’t compete on devices alone, but on intelligence, analytics, and globally scalable business models. Listen to MedTech’s Global Reset: 2025, the year-end episode of HealthPadTalks.
Historically, success in these sectors came not from focus or speed, but from managing complexity. Advantage accrued to those who navigated regulation rather than challenged it, who balanced capital cycles, manufacturing constraints, reimbursement dynamics, and stakeholder politics without destabilising the core. Leaders who rose through this system proved their value by keeping many plates spinning at once. Specialists were inputs. Generalists - especially those fluent in finance, operations, and internal politics - were promoted. This model was rational. It worked. But it was optimised for a world that no longer exists.

The insult persists because the old signals of organisational health remain intact. Revenues still flow. Pipelines advance. Earnings calls still shape strategy. Scale still feels like protection. The erosion, however, is structural rather than cyclical - and therefore easy to dismiss until it accelerates. In this context, political shorthand and familiar put-downs come naturally. They defend status, preserve influence, and avoid the discomfort of confronting unfamiliar sources of advantage.

What has changed is not the presence of complexity, but where advantage is now created. Digital infrastructure, data compounding, platform dynamics, and AI-driven feedback loops reward depth, not diffusion. They favour sustained, almost obsessive focus on a narrow capability until it becomes foundational - and then decisive.

In this environment, calling a strategy a “one-trick pony” is less a warning than a misdiagnosis. It mistakes concentration for fragility and conviction for naïveté. The risk for incumbent healthcare, life sciences, and MedTech organisations is not over-specialisation. It is the false comfort of breadth - defended by habit, politics, and experience - in a world that increasingly punishes it.
 
Technology No Longer Moves on Healthcare Timelines

Over the past three decades, healthcare leadership and mindsets have been shaped by the demands of incremental change. Clinical practice evolves cautiously, regulation moves over years, and scientific breakthroughs often take decades to alter industry structure. Governance is hierarchical, consensus-driven, and designed to minimise downside risk. In a capital-intensive, tightly regulated sector, these disciplines have been not only rational but successful.

Digital, AI, and platform technologies operate on different timelines.

They evolve continuously rather than episodically. Capabilities emerge monthly, not per product cycle. Performance advances through discontinuous jumps driven by data, scale, and usage - not steady linear refinement. In such systems, time itself becomes a source of competitive advantage.

AI improves through deployment, not deliberation. Platforms tip once participation crosses opaque thresholds. Digital infrastructure scales non-linearly: fixed costs are absorbed early, marginal costs fall rapidly, and advantage compounds quietly before becoming suddenly decisive.

This gap is not a failure of intelligence or experience. It reflects a mismatch between mental models forged in relatively stable markets and technologies whose behaviour is dynamic and path dependent. Leaders shaped by decades of capital discipline and regulatory constraint naturally treat technology as an adjunct - layered onto existing operations, governed through pilots, explored broadly, and contained organisationally. The instinct reflects diligence, not neglect, but also limited visibility. When unfamiliar systems are hard to model, boards reach for familiar instruments of stewardship. Optionality feels prudent. Control feels responsible.

In non-linear systems, these instincts are dangerous. Optionality delays learning. Pilots do not compound. Governance slows feedback. Exploration without commitment prevents scale. From inside the organisation, this posture appears careful and defensible; from outside, it looks like inertia.

This is not a new toolset being added to an old operating model. It is a different logic of value creation. The organisations that succeed will not be those that ran the most pilots, but those that recognised early that technology no longer moves incrementally - and reorganised themselves accordingly.
 
Why Yesterday’s Playbook Still Feels Safe

Yesterday’s playbook persists because disruption in healthcare, life sciences, and MedTech rarely arrives as rupture. Core processes continue to function. Products still perform. Regulatory standing holds. Customers do not revolt - and revenue, for a time, continues to flow.
You might also like:
 
This continuity creates an illusion of control. Even as growth slows and value creation flattens, the organisational machinery keeps turning. With no visible breakage, it is easy to conclude that the slowdown is temporary or cyclical - something to be addressed through optimisation rather than rethinking: tighter execution, incremental efficiency, modest investment in familiar domains.
The pace of change reinforces this belief. Because transformation appears gradual, emerging technologies are treated as additive rather than structural - layered onto existing workflows without challenging the operating model. Framed this way, digitalisation, AI, and platform dynamics feel narrow and containable, easily dismissed as a “one-trick pony” rather than recognised as a shift in how advantage is created. This framing is politically convenient. It preserves the legitimacy of current strategies, protects incumbents, and postpones the question of whether the model itself is becoming obsolete.

Meanwhile, erosion occurs at the margins. Cost structures drift upward relative to faster, learning-driven competitors. Decision cycles lengthen. High-calibre talent migrates toward environments with tighter feedback loops and clearer impact. Innovation continues as activity but fails to translate into leverage. None of this raises immediate alarms.

These conditions reinforce confidence in restraint. Leaders point to balance sheets, installed base, and hard-earned experience. Many have lived through capital-intensive hype cycles that promised transformation and delivered little. Scepticism feels prudent - even responsible.

The risk lies here. Early disruption threatens trajectory, not current revenue. It redirects where learning accumulates, where data compounds, and where capabilities deepen long before those shifts register in quarterly metrics. This is the classic precondition for a Kodak-style outcome: apparent stability masking a silent migration of value to a different operating logic.

In healthcare, with long product lifecycles and slow organisational change, this lag is especially costly. Safety persists after its foundations have begun to erode. By the time decline is unmistakable, strategic room has narrowed - and yesterday’s playbook no longer applies.
 
The Early Signals Boards Miss

In regulated industries, early disruption rarely appears as failure. It appears as friction. The signals are subtle, easily rationalised, and often misread as execution issues rather than strategic ones.

Boards tend to focus on lagging indicators: revenue, margin, pipeline progression, regulatory milestones. The leading indicators are different. Learning cycles slow relative to peers. Data assets accumulate without clear ownership or compounding logic. Critical technical decisions are deferred to preserve alignment rather than accelerated to create advantage.

Talent signals often appear first. High-potential operators and technical leaders gravitate toward environments where decisions are fast, tools are modern, and impact is visible. Their departure is often dismissed as cyclical or cultural, rather than strategic.

Partnerships proliferate. Pilots multiply. Centres of excellence emerge. Each is defensible in isolation. Collectively, they signal uncertainty about where to commit. When experimentation outpaces integration, the organisation is exploring without learning - and investing without compounding.

These signals rarely trigger intervention because nothing is visibly broken. Core processes still run. Compliance is intact. Quarterly results remain serviceable. The organisation appears prudent, diversified, and responsive.

It is at this point - when uncertainty rises and conviction wavers - that boards default to strategic breadth as a risk-management reflex. And it is here that the logic inverts.
 
The Fallacy of Strategic Breadth

When uncertainty rises, established organisations default to risk dispersion: multiple initiatives, pilots, and centres of excellence. From a governance standpoint, this reads as responsiveness and prudence. In execution, it delivers the opposite.

Breadth diffuses ownership. Accountability blurs across initiatives never designed to reinforce one another. Learning fragments instead of compounding. Data accumulate without integration or strategic intent. Progress is tracked through activity - programmes launched, pilots funded, partners announced - rather than through mastery or advantage created. To contain this complexity, governance proliferates, further slowing decision-making and feedback.

Over time, technology becomes something the organisation acquires rather than something it operationalises. Capability remains adjacent to the core, not embedded within it. This posture was viable when technological change was slow, learning curves were shallow, and advantage diffused gradually across the sector. That environment no longer exists.

In domains where advantage compounds through data, execution, and learning velocity, progress is path dependent. Early choices shape what becomes possible later. Half-resourced initiatives are not benign hedges; they absorb resources while failing to build anything durable. Optionality is not free. It carries a real - and often invisible - opportunity cost.
 
When Breadth Worked - and Why It Doesn’t Now

Strategic breadth was rational in an era when uncertainty was high and advantage did not compound. Early exploration - regulatory scanning, proof-of-concept work, exploratory partnerships - generated information at low cost. Experiments informed later commitment, and delay carried little penalty. For much of healthcare’s modern history, this was a sensible operating model.

Those conditions no longer hold.
Today, advantage is built through use, not inspection. Capability deepens through execution, not observation. Early focus compounds learning - data, workflows, talent, and organisational muscle - that competitors cannot quickly replicate. In this environment, breadth without commitment is no longer prudent risk management; it is postponed decision-making.

The primary risk has shifted. It is no longer insufficient experimentation, but insufficient conviction.
You might also like to listen to:

HealthPadTalks: Pilot-Grade Leadership
What a One-Trick Pony Looks Like

The caricature of the one-trick pony suggests narrowness and fragility. The reality is the opposite. Enduring technology-driven leaders are specialised systems - engineered to master one complex, foundational problem before expanding from a position of strength.

Retail was not marginally improved by digital platforms; it was reorganised around them. Financial services were not incrementally optimised by data and automation; entire value chains were rebuilt. In each case, the winners were not generalists. They made a choice to concentrate on a constrained problem and pursued it with intensity.

A similar dynamic is now observable in healthcare, life sciences, and MedTech, particularly outside the traditional centres of incumbency. In several fast-developing economies - characterised by rising middle classes, ageing populations, and accelerating disease burden - digitalisation, AI, and platform-based operating models are being adopted early and systemically rather than retrofitted onto legacy structures. The pattern echoes earlier industrial inflection points: not unlike the Japanese automotive manufacturers of the 1970s and 1980s, who converted process focus, learning velocity, and structural coherence into durable advantage over larger US rivals, these newer systems are optimising for rate of learning rather than scale alone.

They aligned structure, incentives, talent, and capital around a single learning curve. They said no – repeatedly - to adjacent opportunities and internal distractions. This was not a lack of ambition. It was ambition expressed with discipline.

Focus creates speed. Speed drives learning. Learning compounds into advantage. In digital and AI-mediated systems, these advantages cannot be assembled after the fact.
 
Why the Critics Are Often Most Exposed

A familiar pattern appears across disrupted sectors. The leaders most likely to dismiss focused digital strategies are often those least structurally able to execute them. Large healthcare, life sciences, and MedTech organisations are optimised for consensus, risk containment, and continuity - not for concentrated execution along a single, compounding learning curve.

Focus is revealing. It exposes constraints in operating models, governance, and executive habits shaped in a pre-digital era. When decisive movement in a narrow domain proves difficult, the strategy is reframed as naïve or incomplete. The critique shifts from feasibility to fit.

Dismissal, then, becomes protective. It stabilises existing power structures and decision rhythms while allowing continuity to pass as prudence. For a time, this appears justified: revenues hold, incremental optimisation satisfies near-term expectations, and erosion remains subtle.

But disruption is rarely gradual. In other industries, legitimacy collapsed abruptly after periods of apparent stability. Healthcare differs in timing, not in direction.

A risk for healthcare enterprises is confusing long tenure with leadership - whether in the executive suite or the boardroom. Time served can harden into institutional reflex: defending standard operating procedures, smoothing over risk, and protecting the familiar rather than staying intellectually current as science, patient agency, data, and AI reshape care. In that climate, accountability can thin out - delays, inefficiencies, compliance breaches, even warning letters are treated as “departmental” issues - leaving senior figures as courteous traffic-controllers of silos rather than owners of outcomes. Yet modern healthcare cannot be run as a comfort-first, innovation-proof posting. Leadership is necessarily uncomfortable: it requires continuous learning, deliberate unlearning, and the courage to retire one’s own processes before they fail patients. Organisations should be alert - especially in recruitment and promotion - to stability without reinvention. That pattern is not loyalty; it is stagnation. The strongest signal is not “hasn’t moved”, but “keeps evolving”: leaders who understand the next operating model, and who accept responsibility when the system falls short.
 
Focus as Leadership

Choosing focus is not a technical choice. It is a leadership decision.

It requires trade-offs - in capital, talent, governance attention, and executive time - and clarity about what the organisation intends to become, not simply what it is preserving. Digital transformation is not additive. It reshapes the core, demanding the retirement of processes, metrics, and structures that no longer accelerate learning.

The so-called one-trick pony accepts this asymmetry. It chooses where to win, aligns around that choice, and accepts that it will not win everywhere else.

Comfort does not confer relevance. Focus does.
 
The Real Risk (Why This Bears Repeating)

This point recurs not because it is easily forgotten, but because it is consistently misunderstood. In healthcare and life sciences, the most dangerous misconception is the belief that competitive advantage erodes slowly, visibly, and with sufficient warning.

In technology-mediated systems, decline is rarely linear and almost never obvious. Data advantages accumulate quietly. Platforms tip without ceremony. AI systems improve incrementally - until thresholds are crossed where human-centred processes shift from assets to structural liabilities. The change is often disguised as continuity, right up until it becomes irreversible.

By the time pressure appears in revenue, margins, or pipeline outcomes, the advantage has already migrated. Capital may still be accessible; time is not.

This is why the risk must be stated repeatedly. Digital and AI-induced change is precipitous because it appears gradual. Disruption penalises hesitation more than error. The cost of moving late is structurally higher than the cost of committing early. Focused organisations move faster not because they are reckless, but because they recognise that in moments of technological transition, decisiveness - not certainty - is the scarce resource.
 
A Challenge to Legacy Leaders

This is not an argument for recklessness. It is a challenge to complacency - the assumption that strategic breadth is safer than prioritising. In periods of technological discontinuity, that assumption inverts.

The governing question is no longer whether a strategy appears narrow, but whether it compounds learning faster than the environment is changing. Breadth manages exposure; focus builds capability. Only one keeps pace with systems that learn.

Legacy organisations are rightly cautious. They carry regulatory responsibility, patient trust, and capital intensity. But caution without commitment becomes drift. And drift, in a compounding environment, is still a decision.

Dismissing focused strategies as “one-trick ponies” may sound sophisticated. Increasingly, it signals something else: an organisation that cannot move with the speed, clarity, and conviction the next era requires.

The choice for leadership is stark and unavoidable: defend comfort - or design relevance.
 
Takeaway

If being a “one-trick pony” means choosing a hard, foundational problem and committing to solve it; aligning the organisation around learning rather than optics; accepting sustained discomfort in service of long-term relevance; and moving at a pace legacy structures resist - then the risk is not focus, but its absence. In compounding environments, indecision is not neutral. Diffused effort does not preserve optionality; it erodes it. Time is not held in reserve by caution - it is spent. Organisations that hesitate in the name of prudence often discover, too late, that they have optimised for continuity while advantage migrated elsewhere. In healthcare, life sciences, and MedTech, this carries weight. Falling behind is not measured only in lost market share or compressed margins, but in installed progress never made, breakthroughs deferred, and patient impact delayed. Leadership in this era is not about managing decline gracefully or hedging every outcome. It is about choosing where to win - and committing before the window narrows beyond recovery.

As digitalisation, AI, and platform models redraw healthcare’s boundaries, the question is no longer whether change is coming. It is whether leaders will commit while advantage is still being formed - rather than explain, later, why it was lost.
view in full page
3 months, 1 week ago

MedTech’s Comfort Crisis

HealthPad
Directory:
Medical Technology
Tags:
AI
analogue mindset
commentary
digital health
Medical Technology
stagnation

  • MedTech’s hidden stagnation: Behind steady revenues and strong compliance lies a crisis - growth has decoupled from innovation
  • The governance paradox: Boards designed for stability and safety now inadvertently suppress strategic renewal and digital transformation
  • The analogue mindset problem: Legacy leadership habits and risk-averse cultures keep MedTech anchored in a manufacturing past
  • Governance without growth: Today’s governance model protects the status quo but fails to build adaptive, data-driven capability for the future
  • From compliance to curiosity: MedTech must evolve its boardrooms and executive teams - redefining fiduciary duty, incentives, and composition - to turn governance into a catalyst for digital-age growth.

MedTech’s Comfort Crisis

On the surface, MedTech has rarely appeared stronger. Revenues are steady, margins solid, compliance rigorous. Boards meet their obligations, regulators are reassured, and investors continue to value the sector’s predictable performance. It is a portrait of success - the kind that populates annual reports with confident language about resilience and long-term value creation.

Yet beneath this stability sits a more uncomfortable truth. As the wider healthcare ecosystem accelerates into the data-driven age, many established, legacy MedTech organisations are losing momentum. Growth is increasingly disconnected from innovation. Digital transformation is referenced as an aspiration rather than an operational reality. Industry acclaim gravitates toward incremental product improvements instead of meaningful, outcomes-driven advances. The result is a subtle but persistent erosion of strategic relevance.

This is MedTech’s silent crisis - not a crisis of failure, but of comfort. Governance remains prudent, compliant, and disciplined, yet it has become designed for continuity rather than renewal, for risk minimisation rather than value creation. In a healthcare landscape rapidly reshaped by data, algorithms, and platform economics, stability is no longer synonymous with strength. Increasingly, it risks becoming a form of strategic stagnation.
 
In This Commentary

This Commentary calls on MedTech boards, CEOs, and investors to rethink how they lead. Its central, if uncomfortable, thesis is that the analogue mindset that built MedTech’s global champions now threatens to constrain their future. To thrive, the sector’s leaders must abandon legacy assumptions and embrace a new, data-driven, platform-based model of value creation.
 
The Value Plateau

For nearly two decades, MedTech was defined by sustained expansion - innovation cycles driven by engineering excellence, reinforced by regulatory moats, and amplified by an era of near-zero interest rates that enabled finance-led M&A. Scale became the dominant strategy, capital was abundant, and valuations rose with reassuring consistency. Growth felt structural, almost inevitable.

That cycle has ended. Despite sound fundamentals, total shareholder returns for many legacy MedTech companies now lag the broader healthcare market - a trend mirrored in McKinsey’s finding that the S&P 500 has outperformed large-cap MedTech every year since 2019. The sector has reached a value plateau: profitable, resilient, but strategically underpowered.

The causes are structural. Product pipelines are increasingly characterised by incrementalism - devices that are smaller, lighter, marginally smarter. Digital, data, or service-led innovation remains the exception rather than the norm. Meanwhile, new entrants - from digital health insurgents to consumer-technology platforms - are redefining how value is created and experienced across the patient and clinician journey. They move faster, iterate continuously, and monetise through models that transcend traditional device economics.

Legacy players, by contrast, continue to measure success through familiar industrial metrics: units shipped, approvals secured, margins defended. Digital initiatives are appended to the core business rather than embedded within it. AI pilots proliferate, but few transition to enterprise-scale transformation.

Markets have adjusted accordingly. Investors now reward predictability not because it inspires confidence in future growth, but because they have stopped expecting innovation-led upside from mature MedTech. Capital that once backed the sector’s R&D engine has shifted toward more dynamic health-tech, data-driven, and platform-based models. What remains is a shareholder base that prizes discipline, efficiency, and cash stability. Boards are applauded for prudence rather than ambition.

The result is a sector configured to preserve value more effectively than it creates it - not a sign of financial fragility, but of strategic stagnation. It reflects an implicit acceptance that many legacy MedTech firms have become custodians of past innovation rather than creators of future advantage.
Quantum computing is moving from lab curiosity to healthcare catalyst, driven by breakthroughs like Google’s Willow chip. LISTEN NOW to the latest episode of HealthPadTalks and discover how quantum computing could accelerate drug discovery, refine diagnostics, advance precision medicine, and transform clinical operations. 
 
The Analogue Mindset

At the heart of today’s stagnation is not a lack of ambition, but a mindset - an operating system shaped by decades of analogue-era success. For more than fifty years, MedTech leaders thrived in a world where companies were fundamentally manufacturers: regulated producers of precision-engineered devices. Winning meant operational excellence, clinical trustworthiness, and global scale.

That legacy built extraordinary organisations. It also forged a leadership identity. The archetypal MedTech executive is an engineer, operator, regulator - or increasingly, a financially trained leader shaped by decades of cost discipline and margin protection. Across the industry, boards remain anchored by auditors, compliance experts, CFOs, and manufacturing veterans. The result is a governance centre of gravity oriented toward control, predictability, and capital efficiency.

In this environment, strategic discussions naturally gravitate toward the familiar terrain of supply chains, inspections, unit economics, and risk mitigation. These capabilities have been essential to MedTech’s rise - but they also reinforce an instinct to optimise the current model rather than reimagine the next one.

This analogue worldview delivered significant achievements: safer devices, unmatched reliability, and global reach. But it also entrenched a narrow conception of innovation - the idea that progress is principally about technical refinement. In a digital economy where value is created through data, connectivity, and user experience, that definition no longer scales. Yet many MedTech companies still frame “digital” as a programme to be managed rather than a core business architecture to be built.

The analogue mindset reveals itself in subtle but telling ways: data teams buried in IT rather than embedded in strategy; digital health units ring-fenced from mainstream product lines; leadership meetings where risk is defined almost exclusively as regulatory exposure rather than competitive opportunity. This is not a failure of capability. It is the natural inertia of a generation that mastered a model the industry long rewarded.

The strategic imperative now is not to defend that mindset, but to recognise it - and consciously reset it. As one industry veteran put it, “We’re still perfecting titanium while the rest of healthcare is wiring the patient.” The organisations that thrive next will be those whose leaders honour the strengths of their analogue heritage while decisively adopting a digital posture for the decade ahead.
 
Governance Without Growth

Governance is designed to safeguard value creation. In MedTech, however, it increasingly constrains it.

Most governance frameworks were built for an era when the primary threat was regulatory, not competitive. Boards were structured to ensure compliance and operational continuity, not to catalyse strategic reinvention. Their composition still reflects that origin: deep expertise in finance, audit, regulatory affairs, and quality systems - but limited fluency in data-driven business models, platform economics, or software-enabled value creation. Risk committees are world-class at interrogating safety, quality, and supply chains, yet less equipped to assess the strategic risk of standing still.
You might also like to listen to:

Synthetic Biology: The Next MedTech Revolution


 
Incentives reinforce this protective posture. Executive compensation remains weighted toward near-term operational metrics - revenue reliability, margin stability, cost discipline. Fewer mechanisms reward capability building, digital integration, or ecosystem positioning. The implicit message is consistent: optimise the model you have, and avoid unnecessary disruption, even as that model loses relevance.

Investors amplify the dynamic. For years, they rewarded MedTech for consistency, resilience, and predictable cash flows. But while many still prioritise stability, they are increasingly signalling discomfort with innovation timelines that lag adjacent sectors. The result is a contradictory pressure: deliver dependable performance today yet somehow transform tomorrow - without visible volatility.
The irony is stark. MedTech boards are among the most disciplined in global industry - processes impeccable, oversight rigorous, risk controls exemplary. Yet this strength has become a strategic constraint. Governance has become so effective at protecting the legacy business that it leaves little bandwidth or imagination to build the future.
 
The Cost of the Analogue Playbook

The consequence of maintaining an analogue playbook is not dramatic collapse but slow strategic drift. MedTech remains essential - but it is gradually moving to the periphery of healthcare’s future unless it adapts with intent.

Innovation leakage. The most valuable data streams now come from wearables, remote monitoring, and digital therapeutics - categories shaped by firms that were born digital and instinctively understand software, behavioural design, and monetisation. Traditional MedTech, built on device excellence, often still views hardware as an endpoint rather than a gateway to continuous, data-enabled care.

Margin pressure. As procurement becomes more price-driven and device differentiation narrows, value is migrating to software, analytics, and integrated services. Digital platform players are capturing recurring revenue streams, while many MedTechs still treat the digital layer as an add-on rather than a core value driver.

Talent imbalance. The most ambitious AI and data talent gravitates toward environments that offer speed, autonomy, and the chance to shape new models. Legacy MedTech organisations - optimised for reliability and risk control - can unintentionally signal rigidity to the innovators they need. The issue is not culture failure but cultural mismatch.

Investor restlessness. Capital markets are recalibrating. While long-term investors have historically prized MedTech’s resilience, they are now looking for credible pathways to digital-led growth. In their place, more reactive capital introduces volatility not seen since the last consolidation wave. The message is measured but unmistakable: operational excellence remains necessary, but it is no longer sufficient.
Strategic marginalisation. If MedTech does not own the patient interface, it risks becoming healthcare’s hardware backbone - still vital, but increasingly interchangeable - while others control the data, relationships, and economics of care.

We have seen this pattern in other industries. Automakers once believed their competitive edge lay in engines, manufacturing scale, and incremental refinement. Then software reframed mobility. Tesla did not replace the car; it redefined what a car is.
You might also like:

Rewriting the Hydrocephalus Playbook
MedTech now faces a similar inflection point. The winners will not abandon their analogue heritage - they will build on it, evolving from precision manufacturers into orchestrators of outcomes across connected, intelligent health systems. The shift is not a repudiation of the past, but a deliberate extension of it.
 
From Governance to Growth: The Adaptive Board

The question is not how governance becomes less rigorous, but how it becomes more strategically relevant. The MedTech boards that lead the next decade will be those that extend their traditional strengths - discipline, accountability, and stewardship - into a posture that actively enables growth.

Reframe fiduciary duty. In a rapidly shifting healthcare landscape, long-term risk management now includes safeguarding the organisation’s capacity to adapt. Strategic inertia is itself a form of value erosion. Modern fiduciary duty means ensuring the enterprise can learn, pivot, and scale new models at market speed - not just protect what already works.

Rewire board composition. Diversity of thought and experience is becoming as important as demographic diversity. Boards benefit when seasoned operators, clinicians, and financial stewards are complemented by directors with deep understanding of data ecosystems, payer economics, and platform business models. This is not about adding a token “digital person,” but enriching the board with peers who can challenge assumptions with equal credibility.

Make governance dynamic. Many MedTech boards excel at internal oversight but have limited exposure to the frontier of innovation. Forward-looking organisations are addressing this by creating Innovation or Technology Committees alongside Audit, Quality, and Risk. Their mandate: steward capability building, evaluate technology bets, and cultivate ecosystem partnerships. This outward orientation - engaging start-ups, academic labs, and tech leaders - signals to emerging talent that the company is serious about shaping the future.

Evolve incentives. Executive rewards need to reflect indicators of transformation - digital revenue mix, speed of capability adoption, partnership depth, and platform maturity. These metrics are not “soft” but correlate with resilience and long-term enterprise value.

Rebalance risk. Traditional governance emphasised variance as danger. Adaptive governance recognises that, in fast-changing markets, stasis can be the greater risk. The goal is not volatility for its own sake, but a calibrated willingness to embrace thoughtful experimentation.

Educate investors. Boards play a critical role in helping capital markets understand the optionality created by transformation. Clear, metric-anchored narratives about capability building, technology integration, and ecosystem expansion can shift investor perception from cost to value creation.

The goal is not reckless governance, but ambidextrous governance - protecting the core while cultivating what comes next. The defining question for the next era is no longer only “Are we compliant?” but also “Are we evolving fast enough?” Traditional strengths remain essential; the opportunity is to redeploy them toward shaping the future rather than merely defending the past.
 
The New Playbook

What does a post-analogue MedTech playbook look like? Above all, it starts with a mindset shift - not from discipline to disruption, but from control alone to controlled curiosity. The organisations that thrive will be those that preserve their operational strengths while opening more space for exploration, learning, and strategic experimentation.

Short term (12 months). Begin by understanding the organisation’s and the board’s digital readiness. How confidently can directors interrogate a data strategy or challenge assumptions about platform economics, patient engagement, or AI-enabled workflows? Many boards are already adding this literacy through briefings, deep dives, and targeted education. Some leading companies complement this with a “digital advisory circle” - a group of next-generation leaders and external experts who bring fresh questions and broaden perspective. At the same time, recalibrate incentives so that transformation outcomes - capability adoption, digital traction, partnership development - sit alongside traditional operational metrics.

Medium term (2–3 years). Shift capital allocation to include structured “learning investments”: small, well-governed experiments in data-driven services, subscription models, AI-enabled care pathways, and cross-sector partnerships. These are not moonshots; they are disciplined probes into the future. Forge alliances with AI start-ups, applied research labs, and digital health accelerators to expand the organisation’s innovation surface area. Redefine innovation KPIs around learning velocity - how quickly teams can test, refine, and scale what works. The emphasis moves from output to throughput: a steady flow of insights, pilots, and proofs of value.

Long term (3–5 years). Evolve the organisational identity. The MedTech leader of the next decade is not just a manufacturer of devices but an orchestrator of outcomes, integrating data, devices, and decision support into connected care experiences. Institutionalise renewal at the board level: ongoing engagement with digital ecosystems, structured immersion in emerging technologies, rotations with start-up observers, and a standing agenda item on organisational learning. This ensures that transformation is not episodic but systemic.

The new playbook is not about abandoning what made MedTech successful. It is about modernising the mental models that sit atop those strengths. The analogue mindset equated control with excellence; the digital era equates learning with longevity. Boards and executives who embrace adaptation as part of their fiduciary role - protecting today while preparing for tomorrow - will define the next chapter of MedTech leadership.
 
Takeaways

MedTech’s challenge is not a failure of intelligence or intent - it is a crisis of imagination. Leaders understand where healthcare is heading, yet legacy systems, incentives, and success patterns can make it difficult to shift at the speed the future now demands. The encouraging truth is that a crisis shaped by governance can be solved through governance. The discipline that delivered MedTech’s reputation for safety, reliability, and trust can now be redeployed to unlock agility, innovation, and growth.

The pivot requires a particular kind of courage: the willingness to recognise that a model designed to protect value may now need to evolve to create it. This is not an indictment of the past, but an invitation to extend its strengths. The future of healthcare will be shaped by leaders who can blend the industry’s traditional assets - clinical credibility, regulatory mastery, operational excellence - with digital fluency, ecosystem thinking, and creative ambition.

Transformation is not disorder; it is competence expressed at a higher tempo. If governance evolves from a posture of compliance to one of informed curiosity, and if investors increasingly reward adaptability alongside predictability, MedTech can once again become a primary engine of healthcare progress.

The end of the analogue mindset is not the end of MedTech - it is the opening of its next chapter. A chapter to be written by leaders confident enough in their expertise to stretch beyond it, and bold enough to evolve before the market forces them to. The future will not belong to those who wait for perfect clarity, but to those who govern with purpose, imagination, and a commitment to continual discovery.
view in full page
11 months, 1 week ago

HealthPadTalks: Macroeconomic Shocks: Building Resilience in MedTech

HealthPad
Directory:
Medical Technology
Tags:
commentary
HealthPadTalks
Medical Technology
MedTech
podcast

In this episode, we explore how healthcare and MedTech companies can strengthen their resilience in the face of global crises. Rather than relying on reactive strategies, the conversation suggests why proactive, forward-thinking preparation is critical for survival and growth.

Macroeconomic shocks - ranging from AI-driven disruptions and pandemics to geopolitical instability and climate-related challenges - are reshaping the landscape of healthcare and MedTech. This episode unpacks the tools and strategies leaders need to navigate these turbulent times, including supply chain diversification, robust intellectual property protection, and adaptive leadership.

In a world defined by uncertainty, the question isn’t if the next shock will come, but when. Are you ready to face what’s next?

view in full page
Loading..
1 comment
Loading..
1 year, 5 months ago

Shaping the Future: MedTech Leadership in a Fast-Changing World

HealthPad
Directory:
Medical Technology
Tags:
Artificial Intelligence
commentary
corporate culture
Machine Learning
Medical Technology
MedTech
  • Navigating the dynamic MedTech landscape demands agility, adaptability, and the ability to manage regulatory shifts, global crises, and rapid technological advancements
  • Leaders must blend forward-thinking with strategic focus, ensuring R&D efforts align with emerging healthcare trends and patient needs
  • Inspiring cross-functional collaboration is important and requires cultivating a culture rooted in accountability, innovation, and ethical responsibility
  • MedTech executives must drive innovation while maintaining rigorous regulatory compliance to protect patient safety and uphold corporate integrity
 
Shaping the Future: MedTech Leadership in a Fast-Changing World

Leading a well-established MedTech company requires a blend of vision, technical expertise, regulatory understanding, agility, and emotional intelligence. While financial acumen is fundamental, what sets exceptional executives apart is their ability to navigate the complexities of healthcare, champion innovation, and maintain a strong ethical foundation. These individuals are not just driving their companies toward commercial success; they are actively shaping the future of healthcare by delivering innovative products that enhance patient outcomes and push the boundaries of medical science.

Cultivating these qualities helps ensure that organisations stay competitive, compliant, and focused on creating real value for patients and healthcare systems. As companies navigate an era defined by rapid technological advancements, shifting regulations, and evolving patient expectations, the ability to lead with integrity and strategic foresight becomes ever more critical. With the right mindset, MedTech executives can not only thrive in this fast-paced environment but also leave a lasting impact on the industry and the future of healthcare.
 
In this Commentary

This Commentary highlights seven key leadership capabilities essential for success in large MedTech companies. With rapid technological advancements, shifting regulations, and increasing demands for better patient outcomes, leaders must balance innovation with regulatory compliance. We emphasise the need for visionary thinking, strategic focus, regulatory expertise, technical knowledge, and emotional intelligence. By cultivating collaboration, adaptability, and ethical responsibility, leaders can steer organisations through disruption, navigate global markets, and drive impactful medical technologies that improve patient outcomes and ensure corporate success.
 
1. Visionary Thinking with a Strategic Focus
 
An effective MedTech executive thrives by combining visionary thinking with strategic execution. Looking beyond the present landscape can open opportunities to anticipate advancements in medical technologies, shifts in healthcare delivery models, and evolving expectations from patients and providers. In a sector driven by innovation, those who can envision the future of healthcare and identify how their companies can contribute meaningfully are well-positioned for success.

Yet, vision alone will not get the job done. Translating ambitious ideas into actionable strategies is essential. This involves setting clear corporate goals, allocating resources wisely, and building the infrastructure to support both immediate operational success and long-term innovation. Balancing growth ambitions with a disciplined approach to risk management and regulatory compliance is especially important in the highly regulated MedTech industry.

Effective portfolio management also plays a role. With a diverse range of products - from medical devices to diagnostic tools - focusing on research and development (R&D) projects that align with both the company’s strengths and emerging healthcare needs is crucial. An understanding of the science behind MedTech and the market forces shaping the industry can positively influence where to invest for future success.
 
2. Mastery of Regulatory and Compliance Issues

Navigating regulatory frameworks presents a challenge in the MedTech industry. With agencies like the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) imposing rigorous requirements for product approval, quality control, and post-market surveillance, understanding these environments is essential. The ability to anticipate policy changes and ensure ongoing compliance can impact a company's success.

Beyond market entry, regulatory mastery helps protect a company's reputation. Ensuring that all departments - particularly R&D, manufacturing, and quality assurance - adhere to strict standards is crucial for safeguarding patient safety and product efficacy. Non-compliance risks fines, product recalls, and reputational damage making a strong grasp of regulatory issues indispensable.
In a global market, navigating international regulations adds another layer of complexity. For instance, the European Medical Device Directive (MDD) requires different compliance measures than those of the FDA in the US. Forward-thinking approach involves preparing teams to meet diverse regulatory demands and working closely with legal, regulatory affairs, and quality management professionals to foster a culture of proactive compliance.
You might also like:
 
3. Technical Savvy and a Commitment to Innovation
 
Innovation is the lifeblood of the MedTech sector. Executives at the helm of large companies benefit from a strong grasp of the technologies driving their products, as well as staying attuned to advancements in medical science and digital health. Staying informed about cutting-edge developments like artificial intelligence (AI), machine learning, robotics, and 3D printing is essential, as these innovations are shaping the future of medical devices and diagnostics.

Encouraging a culture of innovation means fostering an environment where teams can experiment, collaborate across disciplines, and take calculated risks. This atmosphere of exploration allows R&D teams to push boundaries and iterate quickly. Success in this space often involves investing in talent, infrastructure, and strategic partnerships. Collaborating with academic institutions, start-ups, technology companies, or healthcare providers can spark the development of breakthrough technologies and expand a company’s capabilities.

Balancing innovation with regulatory demands is equally important. With MedTech products directly impacting patient health, ensuring that innovations undergo thorough testing and validation is critical. Striking the right balance between speed and safety ensures that new technologies are brought to market efficiently without compromising patient wellbeing.
 
4. Customer-Centricity and Patient Outcomes Focus
 
In today's healthcare ecosystem, MedTech companies are increasingly accountable for the outcomes their products deliver, not just for the products themselves. A strong focus on customer-centricity - whether the customer is a healthcare provider, patient, or payer - has become essential. Shifting priorities toward products and services that improve patient outcomes requires an understanding of end-users, from surgeons operating complex devices to patients managing chronic conditions at home.

Developing solutions that provide real-world benefits involves actively engaging healthcare professionals and patients throughout the product lifecycle, from concept through post-market evaluation. This approach ensures that offerings are not only innovative but also address genuine needs in the clinical setting.

As value-based healthcare models gain traction, with reimbursement increasingly tied to patient outcomes, demonstrating both clinical and economic value is critical. This means providing robust clinical evidence while collaborating with healthcare providers, payers, and policymakers to showcase how MedTech solutions improve patient care and reduce overall healthcare costs.
 
5. Agility in Decision-Making and Crisis Management
 
The MedTech industry is characterised by constant change, driven by rapid technological advancements, evolving regulatory requirements, and unexpected challenges like global health crises. Navigating these complexities demands agility in decision-making, allowing organisations to pivot quickly and remain resilient during periods of uncertainty.

This agility comes from a blend of strategic foresight and operational flexibility. Staying ahead of emerging trends and risks, making informed decisions in real time, and adjusting plans as circumstances evolve are all important. For instance, during the COVID-19 pandemic, many MedTechs shifted their focus to produce essential supplies like ventilators and personal protective equipment  (PPE). This involved reallocating resources, adapting supply chains, and safeguarding the workforce - all while ensuring regulatory compliance.
You might also like:

Reimagining Boards
Effective crisis management also plays a role. Whether facing product recalls, quality issues, regulatory challenges, or broader industry disruptions, the ability to respond swiftly is essential. Clear communication, decisive action, and maintaining the trust of key stakeholders - including employees, healthcare providers, patients, and investors - are crucial in navigating crises successfully.
6. Emotional Intelligence

In the MedTech industry, effective leadership goes beyond strategic decision-making and technical expertise - it also requires emotional intelligence and an ability to lead teams. Inspiring and motivating teams is key to fostering a culture of collaboration, innovation, and accountability, especially in a field where success depends on cooperation between engineers, scientists, regulatory experts, and business professionals.

Emotional intelligence plays a role in this dynamic, enabling self-awareness, empathy, and the ability to manage emotions both personally and within teams. Those who exhibit strong emotional intelligence can build stronger relationships, navigate conflicts with ease, and cultivate a positive organisational culture. This also enhances their ability to communicate vision and goals effectively, uniting teams around a shared purpose.

In larger MedTech companies, managing diverse and geographically dispersed teams requires exceptional communication skills and the capacity to foster cohesion and shared responsibility. Encouraging diversity, equity, and inclusion is also critical, as varied perspectives contribute to stronger problem-solving and drive innovation forward.
 
7. Ethical Integrity and Corporate Responsibility

Given the direct impact MedTech products have on patient health, ethical integrity is essential. Ensuring that corporations uphold the highest ethical standards across all operations - from R&D to marketing - is crucial. This means maintaining transparency in clinical trials, avoiding conflicts of interest, and committing to honest and transparent marketing practices that present both the benefits and risks of products accurately.

Beyond ethics, corporate responsibility also involves sustainability and social impact. MedTech companies must acknowledge their broader role in society, not only in improving health outcomes but also in reducing their environmental footprint and contributing to social good. Manufacturing processes should be assessed for their environmental impact, with efforts made to minimise carbon emissions. Additionally, engaging in corporate social responsibility (CSR) initiatives that promote healthcare access in underserved communities is essential for fostering global health equity.

Maintaining the trust of stakeholders - whether healthcare providers, patients, regulators, or investors - depends on a commitment to ethical practices. In an industry where safety and efficacy are non-negotiable, safeguarding trust is vital for protecting both a company’s reputation and its long-term success.
 
Takeaways

In today's MedTech landscape, financial acumen is no longer a differentiator; it is a baseline requirement. What truly sets leaders apart is their ability to navigate an era defined by rapid technological change and global complexity. The future of MedTech leadership hinges on understanding, embracing, and leveraging new technologies to drive meaningful innovation while maintaining the highest standards of regulatory compliance and patient safety.

The seven leadership traits outlined in this Commentary - visionary thinking, regulatory mastery, technical savvy, customer-centricity, agility, emotional intelligence, and ethical integrity - are more critical than ever. These qualities empower leaders to steer their organisations through disruption, inspire cross-functional teams, and deliver cutting-edge solutions that meet market demands and improve patient outcomes.

In this new era, MedTech executives must go beyond the basics of finance and operations. They must be architects of the future, blending strategic foresight with a deep understanding of the technologies that are reshaping the industry. By fostering a culture of innovation, accountability, and ethical responsibility, these leaders will not only ensure corporate success but also make a lasting, transformative impact on global healthcare.
view in full page
1 year, 11 months ago

The Power of Corporate Culture

HealthPad
Directory:
Medical Technology
Tags:
commentary
corporate culture
Medical Technology
MedTech
  • Corporate culture shapes the identity and values of MedTech companies, influencing their approach to innovation, patient care, and business ethics
  • It encourages robust employee engagement, collaboration, and commitment, crucial for driving advancements in medical technology and enhancing patient outcomes 
  • The alignment of corporate culture with regulatory standards and industry best practices is essential for enterprises to maintain compliance and trust among stakeholders
  • Ethical decision-making and integrity are cornerstones of a positive corporate culture in the MedTech sector, impacting public perception and investor confidence
  • Embracing a supportive and inclusive ethos attracts top talent, nurtures development, and sharpens competitive edge in healthcare's dynamic landscape
 
The Power of Corporate Culture
 
In the ever-evolving environment of the medical technology industry, where innovation and precision are essential, an often underestimated yet indispensable element stands out: corporate culture. It serves as the foundation upon which organisational cohesion and effectiveness are built, encompassing the shared values, beliefs, attitudes, and behaviours that guide employee interactions and shape decision-making processes. A unified corporate environment fosters collaboration, streamlines operations, and boosts productivity, optimising resource allocation and reducing waste. Conversely, fragmented cultures breed discord, hampering communication, impeding progress, and depleting valuable resources in the process. An integrated corporate ethos that empowers individuals and aligns them with the company’s strategic vision can unlock their full potential, nurturing sustainable growth and gaining a competitive edge. 

As the medical technology sector continues its pursuit of innovations and personalised solutions, the role of a robust corporate culture becomes indispensable. It acts as the crucial element for success, helping companies manage challenges effectively while also empowering them to seize opportunities with agility and foresight. Furthermore, a unified corporate ethos strengthens companies to achieve important results that connect with patients and stakeholders, solidifying their leadership role in advancing healthcare and shaping the industry's future.
 
The sustained success of Medtronic, Siemens Healthineers and Boston Scientific in the global MedTech industry partly can be attributed to their distinctive corporate cultures, which serve as a competitive advantage. These companies have strategically cultivated cultures that set them apart from competitors and strike a chord with their stakeholders. For instance, Medtronic's emphasis on innovation and patient-centricity encourages advancements and instils trust among patients and healthcare professionals. Similarly, Siemens Healthineers' commitment to quality and continuous improvement not only drives advancements in medical technology but also ensures reliability and excellence in their products and services. Boston Scientific's focus on integrity, inclusion, and accountability strengthens internal cohesion and enhances customer trust and loyalty. By prioritising values such as collaboration, excellence, integrity, and customer satisfaction, these corporations differentiate themselves within the industry and contribute positively to healthcare outcomes worldwide.
 
In this Commentary

This Commentary highlights the pivotal role of corporate culture in the MedTech industry, advocating for strategies to maximise its impact. It shows how culture can drive success through innovation, employee engagement, and performance. The discussion describes actionable approaches, such as leadership commitment, clear vision, open communication, empowerment, diversity, inclusion, and continuous learning. By implementing these, companies can benefit from culture's potential for sustained growth and innovation, thereby significantly improving healthcare delivery. We present a brief case study of MedCo, a lesser-known UK MedTech, which has gained a reputation for proactive innovation. We illustrate how the company purposefully developed a distinct corporate culture. This differentiated it in an increasingly competitive market, exemplifying the transformative influence of a carefully crafted and implemented corporate culture. Furthermore, the Commentary tackles challenges and provides practical insights to assist enterprises in overcoming these obstacles, directing them toward a culture that promotes innovation, engages employees, and ensures long-term success.
 
Culture a Catalyst for MedTech Success

At its core, corporate culture in MedTechs fuels an environment where employees are inspired to push boundaries, collaborate, and engage in continuous improvement, encouraging creativity and empowering individuals to challenge the status quo. These dynamics facilitate the creation of innovative technologies and solutions poised to improve healthcare delivery. Simultaneously, it nurtures a sense of purpose and belonging within employees, aligning their endeavours with the organisation's mission to advance patient outcomes and elevate quality of life. Corporate ethos can help shape an environment where innovation flourishes, employees excel, and enterprises differentiate themselves. It stimulates collaboration, inspires creativity, encourages quality processes, and promotes continuous improvement, ultimately driving success, and impacting healthcare while building trust, attracting top talent, and strengthening a company's reputation.

Enhanced Employee Engagement and Productivity
When employees feel valued, supported, and appreciated within a positive work environment, they are motivated to contribute their best efforts. Clear communication channels, recognition programmes, and opportunities for professional growth further bolster engagement. A strong corporate culture promotes collaboration, teamwork, and a shared commitment to excellence, leading to increased efficiency and quality output. 
 
Fostering Innovation and Adaptability
Corporate culture is a catalyst for innovation and adaptability by nurturing an environment that values creativity, experimentation, and continuous learning. Employees who are encouraged to think outside the box and challenge conventional norms often generate new ideas and breakthrough solutions.
An ethos that embraces change and risk-taking enables teams to adapt swiftly to evolving market dynamics and technological advancements. Open communication channels and collaboration across departments and functions facilitate the exchange of diverse perspectives and insights, supporting a culture of innovation. Furthermore, an emphasis on learning and development ensures that people remain agile and equipped to manage challenges effectively, driving creativity and adaptability.
You might also like:

Optimising MedTechs’ People Operations for AI and Market Changes
Building Trust and Reputation
By embedding values such as integrity, transparency, and accountability throughout every facet of an enterprise's operations, corporate culture becomes instrumental in promoting trust and shaping reputation, positioning the organisation as a dependable industry partner. When employees observe ethical behaviours and fair treatment they can foster a sense of trust and loyalty. Upholding high standards of conduct and fulfilling commitments enables MedTechs to solidify their reputation as reliable, ethical, and trustworthy entities.
 
Cultivating an Effective Corporate Culture
 
Corporate culture begins at the top and hinges upon the unwavering commitment and alignment of leaders, who serve as the catalysts for its development. Central to this process is the relentless communication of the company's vision, mission, and values, coupled with the demonstration of these principles through leaders' actions. Collaborative goal setting, the establishment of clear objectives, and the implementation of receptive feedback mechanisms all serve to strengthen alignment with organisational objectives and bolster accountability throughout the entire workforce.
 
Open communication channels are essential for promoting transparency and trust. Establishing platforms for candid dialogue, such as regular team meetings and anonymous feedback systems, encourages active participation and fosters an inclusive culture. Leaders play a crucial role by modelling open communication, actively soliciting, and responding to feedback, thus supporting a culture of mutual respect and trust.
 
Employee empowerment lies at the heart of this process. MedTechs can enhance their people by delegating decision-making authority, granting autonomy in tasks, and developing an environment that champions innovation and encourages risk-taking. Recognition programmes that celebrate individual and collective achievements reinforce a culture of appreciation and motivate employees to pursue excellence. Additionally, offering opportunities for career development elevates people to map out their professional growth within the organisation.

You might also like:

The Silent Obstacle to MedTech Growth and Value Creation
Embracing diversity and inclusion stimulates innovation and enhances employee satisfaction and retention. Corporations can implement initiatives such as diverse hiring practices, unconscious bias training, and affinity groups to nurture an inclusive culture where all voices are valued. Mentorship programmes and promoting diverse leadership representation further emphasises an enterprise’s commitment to creating an environment where everyone can excel.
Continuous learning and development are vital for maintaining a culture of growth and improvement. Providing access to training programmes, workshops, and educational resources encourages people to pursue professional development opportunities. Furthermore, cross-functional collaboration and mentorship programmes facilitate the sharing of knowledge, drive innovation, and support continuous professional development.
 
Overcoming Challenges in Developing Corporate Culture

Successfully navigating the complexities of corporate culture development demands a multifaceted approach and steadfast commitment from leaders. Proactively tackling challenges entails more than just addressing them; it requires a strategic orchestration of efforts. Initially, overcoming resistance to change necessitates transparent communication elucidating the rationale behind cultural shifts, while actively involving employees to advance their buy-in and acceptance. Further, dismantling siloed departments and hierarchical structures mandates fostering cross-functional collaboration and flattening organisational hierarchies to promote inclusivity and teamwork. Facilitating an inclusive environment acknowledges and respects cultural differences within diverse teams, promoting a sense of belonging and empowerment. Also, ensuring the longevity and efficacy of cultural initiatives demands consistent reinforcement and alignment with company objectives. And, overcoming resource constraints mandates judicious prioritisation of cultural investments and the efficient utilisation of available resources. By adroitly addressing these challenges and implementing tailored strategies, MedTechs can forge robust corporate cultures that drive success and foster sustainable growth.
 
MedCo: A Case Study

Traditional MedTech enterprises seeking transformative strategies for growth and value enhancement can glean valuable insights from the journey of MedCo. Positioned as a leader in personalised healthcare solutions, the company has forged a successful path by integrating data analytics, genetics, and artificial intelligence (AI) to significantly enhance medical treatments with tailored solutions. However, what distinguishes MedCo is the emphasis its leaders place on corporate culture. Unlike many traditional players who prioritise financial and technological advancements, the company leaders recognise the importance of fostering a dynamic corporate culture that encourages experimentation, embraces diversity, and champions agility. This strategic alignment between technological innovation and a progressive corporate culture has propelled the corporation to the forefront of the industry and enabled it to continuously adapt and prosper in an ever-evolving healthcare ecosystem. Thus, for traditional MedTech enterprises aspiring for transformative growth and value enhancement, the journey of MedCo serves as a testament to the influence of corporate culture in driving innovation and strategic success.
 
With unwavering determination, MedCo's leaders refused to confine themselves to the status quo of conventional healthcare provision. Recognising the transformative potential of corporate culture, they embarked on a journey, fully cognisant that the foundation of such culture rests with leaders, encapsulated by a well-defined vision, mission, and values. Their resolve was to carve out a reputation synonymous with excellence, offering innovative products alongside exceptional service and after-sale support. With a focus on enhancing usability, saving healthcare professionals time and resources, and prioritising patient comfort and emotional wellbeing, the leaders pursued their objectives. They developed a culture characterised by innovation, quality, and employee engagement, which was aligned with the enterprise’s strategic vision.
 
Recognising that corporate culture starts from the highest levels, leaders outlined the company’s vision, mission, and values. Then, through proactive involvement with employees, these principles were collaboratively honed to align with strategic imperatives. Their goal? To forge a legacy characterised by unmatched product excellence, innovation, and comprehensive service: a pledge to substantially enhance usability, mitigate healthcare expenditures, and improve patient outcomes.
 
Establishing open channels of communication emerged as a cornerstone of its cultural blueprint. Town hall meetings, feedback sessions, and online forums became conduits for transparent dialogue, promoting collaboration and encouraging employees to contribute to strategic initiatives. Embracing employee empowerment and recognition, MedCo delegated decision-making authority and celebrated achievements, engendering a culture where every individual felt valued and motivated to take ownership of their contributions. In tandem with strengthening their employees, the company prioritised continuous learning and development, offering comprehensive training programmes, workshops, and mentorship opportunities. This bolstered employee satisfaction and retention and ensured the corporation's continued innovation in a fast-moving sector.
 
The tangible outcomes of MedCo's corporate culture are manifested in elevated levels of employee engagement, heightened productivity, and pioneering innovation. This culture serves as an advantage, attracting top talent, enhancing the company's reputation, and driving technological advancements. This case study is a testament to the transformative potential of corporate culture: a narrative from which traditional MedTechs can glean valuable insights to help in their strategic evolution.
 
Takeaways

Corporate culture is pivotal for MedTech companies, fuelling innovation, engaging employees, and establishing a competitive edge. A cohesive culture, rooted in shared values and collaboration, unleashes companies' full potential for sustained quality growth. Prioritising initiatives like open communication, employee empowerment, and ongoing learning enables firms to tackle challenges, adapt to market shifts, and deliver cutting-edge solutions that improve patient outcomes. A robust corporate culture not only attracts top talent and bolsters reputation but also positions companies as industry leaders. As MedTechs innovate and personalise healthcare, developing and nurturing a vibrant corporate culture remains essential to their mission of transforming healthcare delivery. By embracing corporate culture's power, enterprises can chart a path to sustained success, innovation, and excellence in creating a healthier future.
view in full page
2 years, 2 months ago

Healthcare 2040

HealthPad
Directory:
Medical Technology
Tags:
AI
commentary
genomics
Internet of Things
Machine Learning
Medical Technology
robotics
telemedicine
  • Since 2000 healthcare has been transformed by genomics, AI, the internet, robotics, and data-driven solutions
  • Traditional providers, anchored in outdated technologies, struggle to keep pace with the evolving healthcare landscape
  • Over the next two decades anticipate another seismic shift, bringing further disruptions to medical technology and healthcare delivery
  • In the face of this imminent transformation, risk-averse leaders may cling to outdated portfolios, showing little interest in adapting to a 2040 healthcare ecosystem
  • Providers must decide; embrace change now and thrive in a transformed healthcare landscape, or stick to the status quo and risk losing value and competitiveness
 
Healthcare 2040
 
Abstract

By 2040, the landscape of healthcare will have undergone a seismic shift, discarding antiquated models in favour of cutting-edge AI-genomic-data-driven approaches that will radically change both medical technology and healthcare delivery. This transformation signifies a departure from the conventional one-size-fits-all system, ushering in an era of targeted therapies grounded in molecular-level insights that challenge entrenched healthcare paradigms. The evolving healthcare narrative emphasises prevention, wellbeing, personalised care, and heightened accessibility. This departure from the norm is not a trend but a significant reconfiguration, where the fusion of biomedical science, technology, and expansive datasets merge to facilitate early detection and proactive interventions. This not only deepens our comprehension of diseases but also elevates the efficacy of therapies. At the core of this transformation is the empowerment of individuals within a framework that champions choice and fosters virtual communities. Genetic advancements, far from just addressing hereditary conditions, play an important role in enhancing diagnostic accuracy, optimising patient outcomes, and fundamentally shifting the focus from reactive diagnosis and treatment to a proactive commitment to prevention and holistic wellbeing. The indispensable roles played by genomics and AI-driven care in reshaping healthcare are not isolated occurrences; they will catalyse the emergence of new data-intensive R&D enterprises, which are poised to redefine the healthcare landscape against a backdrop of multifaceted influencing factors. Successfully navigating this transformative period necessitates a distinct set of capabilities and strategic alignment with an envisioned 2040 healthcare environment.

Providers find themselves at a crossroads, confronted with a choice: adapt and thrive or risk losing value and competitiveness in a rapidly evolving landscape. Recognising potential resistance to change and the scarcity of pertinent capabilities, leaders of traditional enterprises must acknowledge that immediate strategic action is not just beneficial but a prerequisite for success in the redefined healthcare ecosystem of 2040. The urgency of this call to action cannot be overstated, as the window of opportunity for adaptation narrows with each passing moment.
 
In this Commentary

This Commentary aims to help healthcare professionals to strategically reposition their organizations for success in the next two decades. Leaders must evaluate their strengths and weaknesses in the context of an envisioned future and implement strategies to align their organisations with the demands of a rapidly changing health ecosystem. Failure to do so will dent enterprises’ competitiveness and threaten their survival. Leaders should anticipate and address resistance to change among executives with a preference for the status quo. The Commentary has two sections: Part 1, Looking Back 20 Years, describes the scale and pace of change since 2000 and emphasises how genomics, the internet, AI, digitalization, data-driven solutions, robotics, telehealth, outpatient services, personalised care, ubiquitous communications, and strategic responses to demographic shifts have transformed medical technology and healthcare delivery. Part 2, Looking Forward 20 Years, seeks to stimulate discussions about the future of healthcare. While we highlight a range of factors positioned to impact medical technology and healthcare deliver in the future, we emphasise the significance of genomics, varied and vast datasets, and AI. We suggest the emergence of specialised agile, AI-driven research boutiques with capabilities to leverage untapped genomic, personal, and medical data. The proliferation of such entities will oblige traditional healthcare enterprises to reduce their R&D activities and concentrate on manufacturing. Over the next 20 years, anticipate an accelerated shift towards patient-centric, cell-based prevention and wellbeing care modalities, large hospitals replaced with smaller hubs of medical excellence, the rapid growth of outpatient centres, and the acceleration of home care and care-enabled virtual communities. The future dynamic healthcare ecosystem necessitates stakeholders to change immediately if they are to survive and prosper. Takeaways posit a choice for healthcare leaders: either stick to the status quo and risk losing value and competitiveness or embrace change and stay relevant.
 
Part 1
 
Looking Back 20 Years

Reflecting on the past two decades shows the rapid evolution and interplay of factors shaping medical technology and healthcare delivery. Appreciating the speed and scale of change helps to envision the future. Factors such as genomics, the Internet, AI, robotics, digitalisation, data-driven health solutions, telehealth, outpatient services, home care, personalised wellbeing, ubiquitous personal telephony, and strategic responses to demographic shifts have all influenced medical technology and healthcare delivery and will continue to do so in the future. Here we describe a few of these factors.

The completion of the Human Genome Project in 2003 was a pivotal moment in the direction of medical advancement, laying the foundations for the emergence of genomics. Genomics, encapsulating the mapping, sequencing, and analysis of DNA, is a pivotal tool for unravelling molecular information, variations, and their implications in both traits and diseases. This achievement not only transformed biomedical research but also changed healthcare, shifting it from a generic one-size-fits-all approach to finely tuned care tailored to the unique genetic makeup of individuals.

Over the past two decades, the decoding of the human genetic blueprint has provided unprecedented insights into diseases at the molecular level, triggering a paradigm shift in medicine. This ushered in an era of personalised and precision approaches to diagnoses, treatments, and prevention. From the advent of targeted therapies to the implementation of genetic screening, genomic research has had a transformative influence and is positioned to continue its impact on healthcare.

Indeed, genomic testing has become a standard practice, and US Food and Drug Administration (FDA)-approved genomic care modalities have advanced medicine. For example, pharmacogenonics tailors drug treatments to individual patients by utilising genetic information, with FDA-approved tests for specific biomarkers that predict medication responses. Hereditary assessments evaluate an individual's cancer risk based on genetic makeup, such as identifying BRCA gene mutations linked to elevated risks of breast and ovarian cancers. Gene expression profiling analyses a patient's tumour genetics to guide targeted cancer therapies, with FDA-approved companion diagnostic tests for specific cancer treatments. Carrier testing identifies genetic mutations that could be passed on to children, which contribute to family planning and prenatal care. Pharmacodiagnostic tests help pinpoint patients that would benefit from specific drug treatments, predicting responses, especially in cancer therapies.

In 2012, the UK government inaugurated Genomics England, an initiative designed to spearhead the 100,000 Genomes Project, which aimed to sequence the genomes of 100,000 patients with infectious diseases and specific cancers. The project’s goals included the enhancement of our understanding of various genetic factors in diseases, the facilitation of targeted treatments and establishing a framework for the integration of genomics into everyday clinical practice. The successful completion of the project in 2018, provided a basis for genomic medicine and a deeper understanding of the genetic framework influencing health and disease.

In addition to genomic data, since 2000, there has been a significant increase in health-related data, driven by the proliferation of electronic health records (EHRs), developments in information management technologies, initiatives to improve healthcare efficiency, and enhanced communications among stakeholders. The growth in data has, in turn, created opportunities for the utilisation of AI and machine learning (ML) algorithms. Over the last two decades, AI has changed medical technology and healthcare delivery by enhancing diagnostics, personalising treatment plans, streamlining administrative tasks, and facilitating research through efficient data analysis, which has improved patient outcomes, and advanced the field. As of January 2023, the FDA has approved >520 AI and ML algorithms for medical use, which are primarily related to the analysis of medical images and videos. Indeed, the rise of algorithms has transformed healthcare, with many of them focusing on predictions using EHRs that do not require FDA approval.

In addition to EHRs there has been the evolution of wearable technologies like the Apple Watch and Fitbit, which have transformed personal health. Initially focusing on fitness tracking, these devices have expanded to monitor an array of health metrics. Over the years, they have amassed vast amounts of personalised data, ranging from activity levels to heart rate patterns. These data reservoirs are a goldmine for healthcare and wellbeing strategies, enabling individuals, healthcare professionals and providers to gain unprecedented insights into health trends, customised care routines, and the early detection of health issues. This combination of technology and health data has created opportunities for proactive healthcare management and personalised wellbeing interventions.

Targeted medicine not only benefitted from AI but also from personalised telephony, which experienced a significant boost in the early 2000s by the widespread internet access in households across the globe. The period was marked by the introduction of the iPad in 2001, closely followed by the launch of the iPhone. These innovations triggered widespread smartphone use and accessible internet connectivity, laying the foundations for the emergence of telehealth and telemedicine. In the early 2000s, global cell phone subscriptions numbered ~740m. Today, the figure is >8bn, surpassing the world's population. This increase was driven by the proliferation of broadband, the evolution of mobile technologies and the rise of social media, all contributing to the ubiquitous presence of the internet. By the 2010s, the internet had integrated into the daily lives of a substantial portion of the global population. Initially, in 2000, ~7% of the world’s population had access online. Contrastingly, today, >50% enjoy internet connectivity. In a similar vein, broadband access in American homes has surged from ~50% in 2000 to >90% in the present day. Personal telephony has evolved into an omnipresent force, and has become an integral part of billions of lives, actively enhancing health and wellbeing on a global scale. After 2010, patient-centric wellbeing evolved and later was helped by Covid-19 pandemic lockdowns, with telehealth and telemedicine offering remote consultations and treatments, empowering patients, and emphasising shared decision-making between healthcare providers and patients.

On a more prosaic level, consider how robotics has changed surgery over the past two decades by offering enhanced precision, reduced invasiveness, and improved recovery times. The use of robotic systems, like the da Vinci Surgical System, which gained FDA-approval in 2000, has allowed surgeons to perform complex procedures with greater accuracy. Between 2012 and 2022, the percentage of surgical procedures using robotic systems rose from 1.8% to 17%. Robotic surgery is becoming increasingly popular, with an annual growth rate of ~15%. In 2020, its global volume was 1.24m, with the US accounting for >70% of all robotic surgeries.

The shifting demographics over the past few decades, marked by decreasing birth rates, prolonged life expectancy, and immigration, has transformed prosperous industrial economies, resulting in a substantial rise in the proportion of the elderly population. For instance, in the US in 2000, there were ~35m citizens ≥65; today, this figure has risen to ~56m, ~17% of the population. Concurrently, there has been an increase of chronic lifetime illnesses such as heart disease, diabetes, cancer, and respiratory disorders. In 2000, ~125m Americans suffered from at least one chronic condition. Today, this figure has increased to ~133m - ~50% of the population. Simultaneously, there is a shrinking pool of health professionals. Research suggests that by 2030, there will be ~5m fewer physicians than society will require. This, together with ageing populations, the growing burden of chronic diseases and rising costs of healthcare globally are challenging governments, payers, regulators, and providers to innovate and transform medical technology and healthcare delivery.
 
Part 2
 
Looking Forward 20 Years

This section aims to encourage healthcare professionals to envision the future. Over the next two decades, medical technology and healthcare delivery are likely to be affected by numerous interconnected factors, which include: (i) continued progress in AI and ML, internet of things (IoT), robotics, nanotechnology, and biotechnology, (ii) advances in genomics, (iii) increasing availability of multi-modal data (genomics, economic, demographic, clinical and phenotypic) coupled with technology innovations, (iv) accelerated adoption of telemedicine and virtual monitoring technologies, (v) changes in healthcare regulations, (vi) an increase of patient-cantered care and greater patient involvement in decision-making, (vii) emerging infectious diseases, antimicrobial resistance, and other global health issues, (viii) Investments in healthcare infrastructure, both physical and digital, (ix) an evolving and shrinking healthcare workforce, including the further integration of AI technologies and changes in roles, (x) economic conditions and healthcare funding, (xi) the ethical use of technology, privacy concerns, and societal attitudes towards healthcare innovations, and (xii) environmental changes and their impact on health and wellbeing. Such factors and their interconnectivity are expected to drive significant healthcare transformation over the next two decades. Healthcare systems throughout the world are tasked with: (i) improving population health, (ii) enhancing patients’ therapeutic journeys and outcomes, (iii) strengthening caregivers’ experience and (iv) reducing the rising cost of care. There appears to be unanimous agreement among healthcare leaders that these goals will not be achieved by business as usual.
 
In November 2023, BTIG, a leading global financial services firm, organised its Digital Health Forum, bringing together >30 healthcare companies that offer a diverse range of products and services. During the event, executives discussed business models, reimbursement, and commercial strategies, and unanimously agreed that: "The market is primed for the mainstream integration of digital diagnostics and therapeutics."  Here we focus on the anticipated accelerated convergence of genomics and AI technologies, and foresee the emergence of agile, AI-driven R&D boutiques as key players in reshaping medical technology and healthcare delivery.
 
These dynamic research entities thrive on the power of data. Currently, ~79% of the hospital data generated annually goes untapped, and medical information is doubling every 73 days. This emphasises the vast latent potential within these repositories. Traditional enterprises and healthcare professionals, constrained by a dearth of data management capabilities, have struggled to unlock the full potential inherent in these vast stores of information. By contrast, the adept data processing capabilities of these new innovative enterprises position them strategically to harness untapped data sources, extracting valuable insights into disease states and refining treatment modalities. Moreover, they boast advanced technology stacks, seamless connections between semiconductors, software, and systems, and are well-prepared to leverage specialised generative AI applications as they emerge in the market. Armed with cutting-edge technology and extensive datasets, they stand ready to enhance diagnostic precision, streamline treatment approaches, and reduce overall healthcare costs. Private equity firms will be eager to invest in these disruptive AI start-ups, anticipating M&A activities focused on specific therapeutic areas that will make them appealing to public markets.

These innovative entities are set to expedite the introduction of disruptive solutions, improve patients' therapeutic journeys, and optimise outcomes while driving operational efficiencies. Anticipate them to overshadow their traditional counterparts, many of which have outdated legacy offerings and historically have treated R&D as small adjustments to existing portfolios. Given that many conventional healthcare enterprises have: (i) failed to keep pace with technological developments, (ii) a dearth of in-house data-handling capabilities, and (iii) no experience in data-heavy disruptive R&D, it seems reasonable to suggest that they will most likely retreat into their core manufacturing activities, relinquish their R&D roles and lose value.

In the forefront of seismic change, the integration of digitalisation, AI, and cutting-edge decision support tools propels the emerging agile, data-driven R&D enterprises into a pivotal role within the landscape of well-informed, personalised healthcare. Meticulously safeguarding sensitive information, these enterprises not only adhere to the highest standards of privacy but also elevate security measures through state-of-the-art encryption techniques and decentralised storage solutions. As staunch guardians of privacy, they go beyond conventional approaches, crafting data repositories that not only shield confidential information but also facilitate the seamless flow of critical insights crucial for advancing medical technology and elevating care delivery. The seamless synergy between vast genomic, economic, demographic, clinical, and phenotypic data repositories and advanced AI techniques is poised to radically change healthcare R&D, redirecting it away from refining traditional products towards disruptive endeavours. Moreover, these agile research entities are anticipated to encourage widespread industry cooperation, harnessing the power of diverse data sources to innovate health solutions and services that transcend boundaries, thereby playing an important role in shaping a borderless health and wellbeing ecosystem.

In the regulatory arena, a transformation is anticipated by 2040. Regulators are likely to evolve from enforcers to stewards of progress, collaborating with industry stakeholders to promote a consumer-centric healthcare. Advocating transparency, patients' rights, and ethical innovation, regulators will become influential drivers of progress, contributing to a shared and equitable healthcare future. This collaborative effort is expected to contribute to a data-driven healthcare ecosystem that prioritises individual wellbeing, innovation, and accessibility in equal measure.

By 2040, expect healthcare payers to have undergone a transformative change, fuelled by a seismic shift in medical technology and healthcare delivery. New payment models will prioritise individualised therapies and patient outcomes, leveraging real-time health data for customised coverage. AI will streamline administration, reduce costs, and enhance overall healthcare efficiency. Increased patient engagement and collaboration among payers, providers, and patients will drive a holistic, patient-centred approach, ultimately improving the quality and accessibility of healthcare services.

This section has emphasised the transformative forces of genomics and AI shaping a personalised healthcare ecosystem. While traditional medical technology and healthcare delivery may be predicated upon physical devices and a one-size-fits-all approach, the future lies in the fusion of data and smart software to accelerate targeted care, which marks a significant departure from the conventional.
 
Takeaways

The shift towards genomic-driven healthcare marks a transformation in the medical landscape expected by 2040. Moving away from outdated models, the trend towards personalised care, rooted in molecular insights, necessitates a revaluation from health professionals. This shift, facilitated by the fusion of biomedical science, advanced technologies, and vast amounts of varied data, foresees a future where prevention, individualised wellbeing, and improved accessibility become the new norm. The convergence of genomics and AI not only improves diagnostics and treatments but also points to prevention and overall wellness. This Commentary has highlighted the transformative impact of genomics and AI-driven healthcare at the cellular level, making way for data-intensive R&D enterprises that will shape the future of medical technology and healthcare delivery. The path to 2040 demands a departure from conventional norms of the past, requiring strategic realignment and specific capabilities. Traditional providers find themselves at a juncture: those that adapt to an envisioned care environment of 2040 are more likely to succeed, while those that resist risk becoming obsolete. By acknowledging potential obstacles to change and the scarcity of relevant capabilities, leaders are encouraged to recognise the urgency of strategic action as a prerequisite for success in the redefined healthcare landscape of 2040. The future is imminent, and the time for transformative readiness is now.
view in full page
2 years, 3 months ago

MedTechs Battle with AI for Sustainable Growth and Enhanced Value

HealthPad
Directory:
Medical Technology
Tags:
AI
Artificial Intelligence
commentary
Machine Learning
Medical Technology
MedTech
MedTechs Battle with AI for Sustainable Growth and Enhanced Value
 
Preface
 
The medical technology industry has experienced significant growth, consistently surpassing the S&P index by ~15 percentage points. This success is rooted in the early 1990s, a time when capital was costly, with interest rates ~10%. However, as we moved closer to 1998, interest rates began to recede, settling just below 7%. This early era of growth was not devoid of challenges. The US was still grappling with the aftermath of the oil embargo imposed in 1973 by the Organization of the Petroleum Exporting Countries (OPEC), which was a response to the American government's support for Israel during the Yom Kippur War and had lasting consequences. The oil crisis triggered hyperinflation, leading to a rapid escalation in the prices of goods and services. In response, the US Federal Reserve (Fed) raised interest rates to a historic high of 17% in 1981, which was aimed at curbing inflation but came at the price of increasing the cost of borrowing. As we entered the 1990s, the landscape shifted. The Fed’s monetary policies began to work, inflation started to decline, and interest rates fell to ~10%, eventually dipping below 7% in 1998. This created conditions for increased investments in research and development (R&D) and the American economy blossomed and benefitted from the internet becoming mainstream. It was during this period that many medical technology companies developed innovative medical devices, which were not only disruptive but also found a receptive global market characterized by significant unmet needs and substantial entry barriers. In the ensuing years, the industry thrived and matured. Fast-forward to the present (2023), and we find ourselves in a different scenario. Over the past five years, numerous large, diversified MedTechs have struggled to deliver value. One explanation for this is that growth of these enterprises over the past three decades, except for the early years, was primarily driven by mergers and acquisitions (M&A), often at the expense of prioritizing R&D. Consequently, many large MedTechs did not leverage evolving technologies to update and renew their offerings and are now heavily reliant on slow-growth markets and aging product portfolios. Navigating a successful path forward would be helped by a comprehensive embrace of artificial intelligence (AI) and machine learning (ML) strategies, since these technologies possess the potential to transform how MedTechs operate, innovate, and serve their stakeholders.
 
In this Commentary

This Commentary explores the role of artificial intelligence (AI) in reshaping the future landscape of the MedTech industry in pursuit of sustainable growth and added value. We focus on the impact AI can have on transforming operational methodologies, fostering innovation, and enhancing stakeholder services. Our aim is to address five key areas: (i) Defining Artificial Intelligence (AI): Describes how AI differs from any other technology in history and sheds light on its relevance within the MedTech sector. (ii) Highlighting AI-Driven MedTech Success: In this section, we preview three leading corporations that have utilized AI to gain access to new revenue streams. (iii) Showcasing a Disruptive AI-Powered Medical Device: Here, we provide an overview of the IDx-DR system, an innovation that has brought disruptive change to the field of ophthalmology. (iv) The Potential Benefits of Full AI Integration for MedTechs: This section briefly describes 10 potential benefits that can be expected from a comprehensive embrace of AI by MedTechs. (v) Potential Obstacles to the Adoption of AI by MedTechs: Finally, we describe some obstacles that help to explain some MedTechs reluctance to embrace AI strategies. Despite the substantial advantages that AI offers, not many large, diversified enterprises have fully integrated these transformative technologies into their operations. Takeaways outline the options facing enterprises.
 
Part 1

Defining Artificial Intelligence (AI)

Artificial Intelligence (AI) is a ground-breaking concept that transcends the simulation of human intelligence. Unlike human cognition, AI operates devoid of consciousness, emotions, and feelings. Thus, it is indifferent to victory or defeat, tirelessly working without rest, sustenance, or encouragement. AI empowers machines to perform tasks once exclusive to human intelligence, including deciphering natural language, recognizing intricate patterns, making complex decisions, and iterating towards self-improvement. AI is significantly different to any technology that precedes it. It is the first instance of a tool with the unique capabilities of autonomous decision making and the generation of novel ideas. While all predecessor technologies augment human capabilities, AI takes power away from individuals.
You might also like:

Forging a path for digital excellence in the MedTech Industry


Unleashing MedTech's Competitive Edge through Transformational Technologies
AI employs various techniques, including machine learning (ML), neural networks, natural language processing, and robotics, enabling computers to autonomously tackle increasingly complex tasks. ML, a subset of AI, develops algorithms that learn, adapt, and improve through experience, rather than explicit programming. The technology’s versatile applications span image and speech recognition, recommendation systems, and predictive analytics. In the quest to comprehend the intersection of artificial and human intelligence, we encounter Large Language Models (LLMs), like ChatGPT, which recently have gained prominence in corporate contexts. These advanced AI models grasp and generate human-like text by discerning patterns and context from extensive textual datasets. LLMs excel in language translation, content generation, and engaging in human-like conversations, effectively harnessing our linguistic abilities.

Part 2

Highlighting AI-Driven MedTech Success

This section briefly describes three examples of MedTechs that have successfully leveraged AI technologies to illustrate how AI’s growing influence drives improvements in accuracy, efficiency, patient outcomes and in the reduction of costs, which together, and in time, are positioned to transform healthcare.
 
Merative, formally Watson Health, a division of IBM that specialised in applying AI and data analytics to healthcare. In 2022, the company was acquired by Francisco Partners, an American  private equity firm, and rebranded Merative. The company leverages AI, ML, and LLMs to analyse extensive medical datasets that encompass patient records, clinical trials, medical literature, and genomic information. These technologies empower healthcare professionals by facilitating more informed decisions, identifying potential treatment options, and predicting disease outcomes. For instance, Merative employs ML to offer personalised treatment recommendations for cancer patients based on their medical histories and the latest research. Integrating LLMs enables natural language processing to extract insights from medical literature, helping healthcare providers stay current with scientific and medical advancements.
 
Google Health, a subsidiary of Alphabet Inc., focuses on using AI and data analysis to improve healthcare services and patient outcomes. It employs AI and ML to develop predictive models that can identify patterns and trends in medical data, which improve early disease detection and prevention. One notable application is in medical imaging, where the company's algorithms can assist radiologists to identify anomalies in X-rays, MRIs, and other images. LLMs are used to interpret and summarize medical documents, making it easier for healthcare professionals to access relevant information quickly. Google Health also works on projects related to drug discovery and genomics, leveraging ML to analyze molecular structures and predict potential drug candidates.
Medtronic is a global leader in medical technology, specializing in devices and therapies to treat various medical conditions. The company incorporates AI, ML, and LLMs into their devices and systems to enhance patient care. For instance, in the field of cardiology, Medtronic's pacemakers and defibrillators collect data on a patient's heart rhythms, which are then analyzed using AI algorithms to detect irregularities and adjust device settings accordingly. This real-time analysis helps to optimize patient treatment. Medtronic also employs AI in insulin pumps for diabetes management that can learn from a patient's blood sugar patterns and adjust insulin delivery accordingly. Additionally, LLMs are used to extract insights from electronic health records (EHR) and clinical notes, which help healthcare providers to make more personalized treatment decisions.
You might also like:
 
 
Part 3

Showcasing a Disruptive AI-Powered Medical Device

AI has been applied to various medical imaging tasks, including interpreting radiological images like X-rays, CT scans, and MRIs and there are numerous AI-driven medical devices and systems that have emerged and evolved in recent years. As of January 2023, the US Federal Drug Administration (FDA) has approved >520 AI medical algorithms, the majority of which are related to medical imaging. Here we describe just one, the IDx-DR system, which was developed by Digital Diagnostics. In 2018, it became the first FDA-approved AI-based diagnostic system for detecting diabetic retinopathy. If left untreated, the condition can lead to blindness. Globally, the prevalence of the disease among people living with diabetes is ~27% and every year, >0.4m people go blind from the disorder. In 2021, globally there were ~529m people with diabetes, which is expected to double to ~1.31bn by 2050.
 
The IDx-DR device utilizes AI algorithms to analyze retinal images taken with a specialized camera and accurately detects the presence of retinopathy that occurs in individuals with diabetes when high blood sugar levels cause damage to blood vessels in the retina. Significantly, the device produces decisions without the need for retinal images to be interpreted by either radiologists or ophthalmologists, which allows the system to be used outside specialist centres, such as in primary care clinics. Advantages of the system include: (i) Early detection, which can improve outcomes and quality of life for individuals with diabetes. (ii) Efficiency. The system analyzes images quickly and accurately, providing results within minutes, which allows healthcare providers to screen a larger number of patients in a shorter amount of time. (iii) Reduced healthcare costs. By detecting retinopathy at an early stage, the system helps prevent costly interventions, such as surgeries and treatments for advanced stages of the disease, which can lead to significant cost savings for healthcare systems. (iv) Patient convenience. Patients undergo retinal imaging as part of their regular diabetes check-ups, reducing the need for separate appointments with eye specialists, which encourages enhanced compliance.
 
Part 4

The Potential Benefits of Full AI Integration for MedTechs

Large, diversified MedTechs stand to gain significant benefits by fully embracing AI technologies that extend across all aspects of their operations, innovation, and overall value propositions. In this section we briefly describe 10 such advantages, which include enhanced innovation, improved patient outcomes, increased operational efficiency, cost savings, and access to new revenue streams. Companies that harness the full potential of AI will be better positioned to thrive in the highly competitive and rapidly evolving healthcare industry.
 
1. Enhanced innovation and product development
AI technologies have the potential to enhance R&D endeavours. They accomplish this through the ability to dig deep into vast repositories of complex medical data, identifying patterns, and forecasting outcomes. This translates into a shorter timeline for the conception and creation of novel medical technologies, devices, and therapies. In essence, AI quickens the pace of innovation in healthcare. The capabilities of AI-driven simulations and modeling further amplifies its impact. These virtual tools enable comprehensive testing in a digital environment, obviating the need for protracted physical prototyping and iterative cycles, which can shorten the development phase and conserve resources, making the innovation process more cost-effective, and environmentally sustainable.
 
2. Improved patient outcomes
Beyond improving the research landscape, AI improves the quality of patient care by enhancing diagnostic precision through the analysis of medical images, patient data, and clinical histories. Early detection of diseases becomes more precise and reliable, leading to timelier intervention and improved patient outcomes. Additionally, AI facilitates the personalization of treatment recommendations, tailoring them to individual patient profiles and current medical research. This optimizes therapies and increases the chances of successful outcomes and improved patient wellbeing.
 
3. Efficient clinical trials
Increasingly AI algorithms are being used in clinical studies to identify suitable patient cohorts for participation in trials, effectively addressing recruitment challenges and streamlining participant selection. Further, predictive analytics play a role in enhancing the efficiency of trial design. By providing insights into trial protocols and patient outcomes, AI reduces both the time and costs associated with bringing novel medical technologies to market, which speeds up the availability of treatments and facilitates the accessibility of healthcare innovations to a broader population.
 
4. Operational efficiency
Operational efficiency is improved with the integration of AI technologies by refining operations. AI-driven supply chains and inventory management systems play a significant role in optimizing procurement processes. They analyze demand patterns, reduce wastage, and ensure the timely availability of critical supplies. By doing so, companies can maintain uninterrupted operations, enhancing their overall efficiency and responsiveness. Another component of operational efficiency lies in predictive maintenance, which can be improved by AI. Through continuous monitoring and data analysis, AI can predict equipment failures before they occur. Such a proactive approach minimizes downtime and ensures manufacturing facilities remain compliant and in optimal working condition. Consequently, healthcare providers experience improved operational efficiency, strengthened compliance, and a reduction in costly disruptions. The automation of routine tasks and processes via AI relieves healthcare professionals from repetitive duties and frees up resources that can be redirected towards more strategic and patient-centric initiatives. This reallocation reduces operational costs while enhancing the quality of care provided.
 
5. Cost savings
Beyond automation, AI-driven insights further uncover cost efficiencies within healthcare organizations. AI identifies areas where resource allocation and utilization can be optimized, which can result in cost reduction strategies that are both data-informed and effective. AI's potential extends to the generation of innovative revenue streams. Corporations can develop data-driven solutions and services that transcend traditional medical devices. For instance, offering AI-driven diagnostic services or remote patient monitoring solutions provides access to new revenue streams. Such services improve patient care and contribute to the financial sustainability of enterprises. Further, AI-enabled healthcare services lend themselves to subscription-based models, ensuring consistent and reliable revenue over time. Companies can offer subscription services that provide access to AI-powered diagnostics, personalized treatment recommendations, or remote monitoring, which have the capacity to diversify revenue streams and enhance longer-term financial stability.
 
6. New revenue streams
AI's ability to analyze vast datasets positions MedTechs to unravel the interplay of genetic, environmental, and lifestyle factors that shape individual health profiles. With such knowledge, personalized treatment plans and interventions can be developed, ensuring that medical care is tailored to each patient's unique needs and characteristics. This level of customization optimizes outcomes and minimizes potential side effects and complications. AI's ability to process vast amounts of patient data and detect patterns, anomalies, and correlations, equips healthcare professionals with the knowledge needed to make more informed decisions. Such insights extend beyond individual care, serving as the basis for effective population health management and proactive disease prevention strategies. In short, AI transforms data into actionable intelligence, creating a basis for more proactive and efficient healthcare practices.
You might also like:

Leaning-in on digital and AI
7. Regulatory compliance and safety
In an era of stringent healthcare regulations, AI is a reliable ally to ensure compliance and enhance safety standards. Through automation, AI streamlines documentation, data tracking, and quality control processes, reducing the risk of errors and oversights. Also, AI-powered systems excel in the early detection of anomalies and potential safety issues, which increase patient safety and the overall quality of healthcare solutions and services. This safeguards patient wellbeing and protects the reputation and credibility of companies.
8. Competitive advantage
MedTechs that are early adopters of AI stand to gain a distinct competitive advantage. They can offer AI-powered solutions and services that deliver superior clinical outcomes and improve overall patient experience. By harnessing the potential of AI, companies can position themselves as leaders in innovation and technological capabilities, likely drawing a loyal customer base, valuable partnerships, collaborations, and investments.
 
9. Talent attraction and retention
Embracing AI technologies also has an impact on talent attraction and retention. The allure of working on novel AI projects that improve lives attracts scarce tech-savvy professionals who seek to be part of dynamic, purposeful, and forward-thinking teams. Such talent contributes to a skilled workforce capable of extending the boundaries of AI innovation within MedTech companies. Further, fostering a culture of innovation through AI adoption encourages employee engagement and job satisfaction, leading to improved talent retention.
 
10. Long-term sustainability
The integration of AI goes beyond immediate advantages; it positions MedTechs for longer-term strategic growth and resilience. As the healthcare landscape continues to evolve, adaptability and innovation become more important. AI enables companies to adapt to changing market dynamics, navigate regulatory challenges, and remain relevant amidst industry transformations. By staying at the forefront of technological advancements, companies ensure their relevance and contribute to shaping the future healthcare landscape.
 
Part 5

Potential Obstacles to the Adoption of AI by MedTechs

The integration of AI technologies into numerous industries has demonstrated its potential to significantly enhance operations, improve R&D, and create new revenue streams. However, despite AI’s potential to contribute significant benefits for business enterprises, its adoption by many large, diversified medical technology companies has been limited and slow. This section describes some factors that help to explain the reluctance of senior MedTech executives to fully embrace AI technologies, which include an interplay of organizational, technical, and industry-specific issues. Without overcoming these obstacles, MedTechs risk losing the growth and value creation they once experienced in an earlier era.

Demographics of senior leadership teams
According to Korn Ferry, an international consultancy and search firm, the average age for a C-suite member is 56 and their average tenure is 4.9 years, although the numbers vary depending on the industry. The average age of a CEO across all industries is 59. If we assume that the MedTech industry mirrors this demographic, it seems reasonable to suggest that many corporations have executives approaching retirement who may be more risk averse and oppose the comprehensive introduction of AI technologies due to a fear of losing benefits they stand to receive upon retirement.

Organizational inertia and risk aversion
Large medical technology companies often have well-established structures, processes, and cultures that resist rapid change. In such an environment, executives might be hesitant to introduce AI technologies due to concerns about disrupting existing workflows, employee resistance to learning new skills, and the fear of failure. The risk-averse nature of the medical technology industry, where patient safety is critical, further amplifies executives' cautious approach to implementing unproven AI solutions.
 
Technical challenges and skill gaps
AI implementation requires technical expertise and resources. Many MedTech executives might lack a deep understanding of AI's technical capabilities, making it difficult for them to evaluate potential applications. Further, attracting and retaining AI talent is highly competitive, and the scarcity of professionals skilled in both medical technology and AI can hinder successful implementation.
Regulatory and ethical concerns
The medical field is heavily regulated to ensure patient safety and data privacy. Incorporating AI technologies introduces additional layers of complexity in terms of regulatory compliance and ethical considerations. Executives might hesitate to navigate these legal frameworks, fearing potential liabilities and negative consequences if AI systems are not properly controlled or if they lead to adverse patient outcomes.
Long development cycles and uncertain ROI
The R&D cycle in the medical technology industry is prolonged due to rigorous testing, clinical trials, and regulatory approvals. Although AI technologies have the capabilities to enhance R&D efficiency, they can introduce additional uncertainty and complexity, potentially extending development timelines. Executives could be apprehensive about the time and resources required to integrate AI into their R&D processes, especially if the return on investment (ROI) remains uncertain or delayed.
 
Industry-specific challenges
The medical technology industry has unique challenges compared to other sectors. Patient data privacy concerns, interoperability issues, and the need for rigorous clinical validation can pose barriers to AI adoption. Executives might view these complexities as additional hurdles that could hinder the successful implementation and deployment of AI solutions.
  
Existing Revenue Streams and Incremental Innovation
Many large, diversified MedTechs generate substantial revenue from their existing products and services. Executives might be reluctant to divert resources towards AI-based ventures, fearing that these investments could jeopardize their core revenue streams. Additionally, a culture of incremental innovation prevalent in the industry might discourage radical technological shifts like those associated with AI.
 
Takeaways
 
Hesitation among MedTechs to integrate AI technologies poses the threat of missed opportunities, diminished competitiveness, and sluggish growth. This reluctance hinders innovation and limits the potential for enhanced patient care. Embracing AI is not an option but a strategic imperative. Failure to do so means missing opportunities to address unmet medical needs, explore new markets, and access new revenue streams. The potential for efficiency gains, streamlined operations, and cost reductions across R&D, manufacturing and supply chains is significant. Companies fully embracing AI gain a competitive advantage, delivering innovative solutions and services that improve patient outcomes and cut healthcare costs. Conversely, those resisting AI risk losing market share to more agile rivals. AI’s impact on analysing vast amounts of complex medical data, accelerating discovery, and enhancing diagnostics is well established. MedTechs slow to leverage AI may endure prolonged R&D cycles, fewer breakthroughs, and suboptimal resource allocation, jeopardising competitiveness and branding them as ‘outdated’. In today’s environment, attracting top talent relies on being perceived as innovative, a quality lacking in AI-resistant MedTechs. As AI disrupts industries, start-ups and smaller agile players can overtake established corporations failing to adapt. A delayed embrace of AI impedes progress in patient care, diagnosis, treatment, and outcomes, preventing companies from realising their full potential in shaping healthcare. The time to embrace AI is now to avoid irreversible setbacks in a rapidly evolving MedTech ecosystem.
view in full page
Loading..
1 comment
Loading..
2 years, 4 months ago

The Silent Obstacle to MedTech Growth and Value Creation

HealthPad
Directory:
Medical Technology
Tags:
commentary
Medical Technology
MedTech
  • The MedTech industry has undergone a transformative journey marked by prolific mergers and acquisitions (M&A)
  • Between 2006 and 2016, the industry witnessed 2,680 acquisitions totaling US$607.8bn
  • In the pursuit of efficient integrations corporations often overlooked the significance of fostering a distinct organisational culture
  • In many cases this resulted in cultural dissonance, which is a silent but substantial obstacle to growth and value creation
  • Stories can overcome this obstacle and help to bridge gaps, align interests, and cultivate a shared sense of purpose among employees and stakeholders for long-term MedTech success
 
 The Silent Obstacle to MedTech Growth and Value Creation
 
The MedTech industry, marked by decades of prolific mergers and acquisitions (M&A), has undergone a transformative journey fuelled by factors like the pursuit of economies of scale, technological access, and navigating regulatory challenges. While strategic consolidations have yielded financial and organisational benefits, often they have inadvertently overlooked the softer facet of corporate identity - organisational culture.
 
Illustrating the magnitude of M&A within the industry, the decade from 2006 to 2016 witnessed 2,680 acquisitions with a value totaling US$607.8bn. Noteworthy is the consistency in the frequency of these acquisitions, juxtaposed against the variability in the consideration of individual deals.
                                                                                                                     
By 2023, a notable shift occurred within the MedTech M&A landscape. The deceleration of M&A activity led to a saturation in market segments with products and services, which intensified competition for market share and exerted pressure on pricing and profit margins. As the M&A market cooled, the accessibility to cutting-edge technologies became more elusive, putting companies at a disadvantage in terms of product development and maintaining competitiveness. Simultaneously, heightened geopolitical tensions and trade restrictions further complicated supply chains and distribution channels. The constrained M&A environment raised hurdles for expanding into emerging markets, which narrowed potential growth opportunities. Integrating talent from acquired companies, a common practice in M&A, also faced challenges amid the slowdown, which impacted the ability to sustain a competitive edge in expertise and innovation. Without the efficiency gains typically associated with M&A, numerous companies encountered escalating cost pressures, which encompassed R&D costs, manufacturing expenses, and other operational outlays that adversely affected overall profitability. The heighted expectations from shareholders for consistent growth, a hallmark for large diversified MedTechs, faced added difficulties due to the deceleration of M&A activity, potentially influencing stock prices and investor confidence.
 
Periods of integrating acquired enterprises tend to be dominated by the pursuit of efficiency, cost savings, and regulatory compliance, which often means relegating the significance of cultivating a distinct and cohesive organisational culture. In the current landscape, where M&A activity has decelerated and corporate values have plateaued, the ramifications of this neglect are becoming increasingly evident. Some enterprises are finding themselves with fragmented cultures, which have low levels of solidarity: employees disagree about organisational objectives, critical success factors, and performance standards. This can make organisations challenging to manage, and leaders unable to affect change. Organisational culture is not simply rhetoric; it is a critical element that molds how employees perceive their roles, comprehend their company's mission, and ultimately contribute to innovation and value creation. Further, a robust and distinctive culture plays a role in attracting and retaining top talent. In an industry driven by innovation, retaining the brightest minds is important for success. When employees sense a misalignment between their personal values and the organisational culture, it can result in disengagement, increased turnover rates, and a depletion of institutional knowledge - all of which undermine long-term growth.
 
Consider this scenario: A MedTech company with a clear and supportive culture is well equipped to navigate the intricacies of the industry. Such an environment fosters a shared sense of purpose and identity among employees, creating a collaborative space where diverse talents can thrive. This, in turn, augments a company's capacity to adapt to industry changes, respond to emerging healthcare needs, and drive sustainable value creation.
 
Culture embodies community; it is the essence of how individuals connect with each other. Flourishing communities arise from shared interests, mutual obligations, and a foundation of cooperation and camaraderie. A common oversight in certain management literature concerning corporate culture is the assumption that organisations are inherently homogeneous. However, just as one organisation differs from another, so do its internal units. Consider the contrasting nature of, for instance, the R&D function compared to manufacturing within a MedTech company. Moreover, hierarchical distinctions within an enterprise add layers of diversity; the cultural dynamics of senior leadership teams may differ markedly from those of middle managers and blue-collar workers.
 
In the MedTech industry, where financial and organisational factors maintain their importance, a strategy that develops a distinctive organisational culture is equally important. Overlooking cultural integration presents a nuanced yet potentially significant barrier to growth and value creation. This challenge manifests itself through indicators such as disengaged employees, talent attrition, and a lack of adaptability in meeting the evolving demands of the industry. Recognizing and addressing this cultural deficit extends beyond employee satisfaction; it emerges as a strategic imperative for long-term success in the dynamic landscape of MedTech.
 
Further, as corporations expand globally they encounter challenges to unite and motivate their constituencies. Internationalization means transcending geographical, linguistic, cultural, and religious boundaries. Multinational corporations operate in a world where employees are from various countries, speak different languages, and possess diverse cultural backgrounds, which emphasises the significance of establishing common ground and fostering a sense of belonging. Moreover, modern organisations are linked to an array of stakeholders, including governments, patients, insurance firms, advocacy groups, and a wide spectrum of customers. These often hold distinct interests and priorities, occasionally leading to conflicts with both each other, and the organisation's objectives.
You might also like:

Forging a path for digital excellence in the MedTech Industry

 
The power of stories

In this interconnected ecosystem, a cohesive and inspiring narrative emerges as a potential remedy for dissonance. A well-crafted story has the capacity to bridge divides, align interests, and instil a collective sense of purpose among both employees and stakeholders. This, in turn, contributes to a corporation's overall success.
The impact of a unifying narrative does not confine itself to an organisation's internal boundaries. It acts as a catalyst for collective action, motivating employees, and stakeholders alike toward shared objectives. This shared story becomes the driving force behind innovation, it bolsters problem-solving capabilities, and shapes the organisation into a responsive and adaptable entity. In a world where trust, differentiation, innovation, talent attraction, stakeholder engagement, and customer loyalty wield substantial influence, a captivating narrative emerges as a positive force for a diversified MedTech company. It adeptly communicates the company's mission, values, and impact, establishing trust, distinguishing the brand, fostering innovation, attracting top talent, engaging stakeholders, and cultivating customer loyalty. Ultimately, it solidifies a company's brand identity, nurtures relationships, and fuels long-term commercial success.
 
The potency of an inspiring company narrative lies in its ability to weave a common thread through the diverse interests of employees, creating unity and a shared company culture. A compelling story acts as a connective tissue, transcending departmental and hierarchical boundaries, resonating universally regardless of individual roles or backgrounds. Such narratives instill a collective sense of purpose and pride, fostering a shared identity embraced by every employee. When everyone is tethered to a common story, it encourages a cohesive culture where values and goals are not just communicated but lived and upheld by each member of the organisation. This shared narrative becomes a wellspring of motivation, aligning the workforce toward a singular vision and propelling the company forward as a unified and harmonious entity.
 
These claims may seem exaggerated when applied to a company narrative. However, to grasp the potential impact of storytelling, let us briefly examine the realms of religion, politics, finance, and the women’s movement. All these domains are predicated upon narratives that not only inspire and motivate diverse groups of individuals but also make them reshape their lives and dedicate their time and energy to the causes these narratives portray.
 
Religion

Religion plays an important part in the spiritual lives of billions of people around the world. Religious stories hold a significant influence over the beliefs and practices of faith communities, providing them with a sense of meaning and purpose. The potency of a narrative's impact is exemplified in the case of Jerusalem, a city that embodies the enduring power of stories.
 
For Jews, Jerusalem is a testament to the divine intervention of their narrative, where God commanded Abraham not to sacrifice his son Isaac. For Christians, Jerusalem holds multifaceted significance across various church factions, but it universally marks the hallowed ground where Jesus Christ delivered his teachings and shared the Last Supper with his disciples before his crucifixion. Similarly, for Muslims, Jerusalem bears importance as the place where the Prophet Mohammad started his mission and experienced a divine vision.
 
What is striking about these narratives is that they have endured through centuries, despite the absence of any scientific evidence, relying on the power of spiritual belief. This emphasises the influence of storytelling. People hold these stories dear to their hearts, embracing them with unwavering faith. Such narratives have the power to shape cultures, societies, and even geopolitical landscapes. The enduring power of religious narratives, like those surrounding Jerusalem, teaches us that stories are more than tales, but the scaffolding upon which belief systems are constructed, and they have the potential to move nations and shape destinies.
 
Politics

Consider politics. Political ideologies are founded upon stories that individuals hold so firmly that they are prepared to resolutely defend their convictions, even at the cost of armed conflict. These ideologies shape the governance, policies, and destinies of nations, and their power lies in the stories they tell.
 
Consider democracy, for instance. It is a powerful narrative that extols the virtues of power vested in the hands of the people or their elected representatives. Democracy's story emphasizes principles of equality, individual rights, and the regular exercise of those rights through elections. It speaks to the idea that citizens should actively participate in shaping their government and society through voting and civic engagement. This narrative has led people to fight for democratic values, even in the face of oppressive regimes, as they believe in the story of democracy's inherent worth.
 
Socialism is another political ideology grounded in a compelling narrative. It advocates for collective or state ownership and control of the means of production, distribution, and exchange. The story of socialism centres on reducing economic inequality and ensuring that resources and wealth are more equitably distributed among society's members. This narrative has inspired revolutions, social movements, and political changes across the world, as believers are motivated by the story of a fairer and more just society.
 
In contrast, authoritarian states are political systems characterised by centralised power and limited political freedoms. They too are predicated on stories. Such states often feature a single leader or a small group of individuals with substantial control over the government, little or no opposition, restricted civil liberties, and limited or no free elections. They prioritize order and control over individual rights and freedoms, often relying on censorship, propaganda, and coercion to maintain their authority. Despite its repressive nature, it has garnered fervent adherents who are willing to defend their vision of a disciplined and ordered society, sometimes at great human cost.
 
These political narratives are strong forces that shape the world we live in. They are stories that compel people to action, and at times, to support and engage in conflict. Understanding the power of these narratives is essential for comprehending the dynamics of political movements, governance, and global affairs. It emphasises that the stories we believe in are not just words; they are forces capable of reshaping societies and history itself.
 
Money

Money, in its essence, is a symbol devoid of inherent value. Take a $100 bill, for instance. It possesses no intrinsic worth; you cannot eat it, clothe yourself with it, or find shelter beneath its folds. In today's digital age, most monetary transactions occur virtually, further emphasizing that money is not a tangible commodity but a representation of value. What makes money intriguing is that its value is predicated upon a story, a narrative that commands the largest following worldwide, surpassing the collective adherents of all religions combined. Money, in essence, is a story with believers numbering billions.
 
This narrative begins with the idea that a particular piece of paper or digital entry holds value. It is a shared belief system, one upheld by individuals, corporations, and governments across the globe. This shared belief is what allows us to exchange money for goods, services, and even intangible assets like trust or promise. Consider the notion of a banknote. Its value exists because we believe in the authority and stability of the issuing government or institution. It is a mutual understanding that a piece of paper, despite its lack of intrinsic value, can be exchanged for something tangible or intangible in the real world.
 
This shared belief in money's value creates a complex web of economic interactions and relationships. It fuels trade, investment, and economic growth. It enables people to plan, save for retirement, and invest in education and healthcare. Money, as a story, is a unifying force in the modern world, transcending borders, cultures, and languages. Yet, like all narratives, money is not without its challenges and contradictions. Economic disparities, financial crises, and questions about the fairness of wealth distribution persist. But the fact remains that money, as a story, is a force of unparalleled influence, guiding the decisions and actions of individuals and nations alike. In a world where the value of money is woven into the fabric of society, it becomes clear that its true worth lies not in the physical notes or digital records but in the collective trust and beliefs that sustain this narrative. Money, in the end, is a story that shapes our lives, economies, and the world at large.
 
Women’s movement

The women's movement is a testament to the power and influence of a story about equality. Over decades, this movement has enhanced the status of women worldwide. What makes this narrative particularly interesting is that, unlike the stories underpinning religion, politics, and money, the pursuit of women's rights has largely been achieved through peaceful means, which is a testament to the millions of people around the world who embraced the story that activists told.
 
The narrative of the women's movement is simple: equality. It tells a story of a world where women and men stand on equal footings, where gender should not be a barrier to opportunities, rights, or dignity. This story resonated with countless individuals who recognized the inherent justice in this vision. The power of this story lies in its ability to inspire action. It mobilized women and men from all walks of life to come together and advocate for change. Grassroots activists, iconic leaders, and ordinary citizens joined forces, fuelled by the belief in the story's inherent truth. They organised rallies, signed petitions, and engaged in peaceful demonstrations, all with the goal of dismantling systemic inequalities and securing equal rights for women.
 
What sets the women's movement apart from many other stories that shape our world is its peaceful nature. While religious, political, and economic narratives have often been associated with conflict and violence, the women's movement has predominantly relied on peaceful activism and advocacy. This nonviolent approach has garnered widespread support and sympathy from people of diverse backgrounds, fostering a sense of unity and shared purpose.
 
The influence of this narrative has been significant. It has led to legal and societal changes, from suffrage and reproductive rights to workplace equality and gender representation in leadership roles. Women's rights have advanced on a global scale, improving the lives of millions. The women's movement is a powerful example of how a story can shape the world when embraced by a collective of individuals who believe in its message. It demonstrates that narratives grounded in principles of justice and equality can bring about transformative change, even without resorting to violence. The women's movement serves as a reminder that stories have the power to move societies and bend the arc of history toward progress and justice.
 
Takeaways

The MedTech industry's journey through decades of M&A activity has been a transformative one, marked by the pursuit of economies of scale, technological access, and regulatory mastery. The resulting financial and organisational benefits, however, have inadvertently overlooked a critical aspect: organisational culture. The magnitude of M&A activity, exemplified by 2,680 acquisitions totaling US$607.8bn between 2006 to 2016, showcases both consistency and variability in deal considerations. As we fast forward to 2023, global uncertainties prompted a recalibration of strategic initiatives, especially as MedTech companies aimed for operational scaling and global expansion. The challenges of uniting diverse constituencies in an internationalized context - spanning geographical, linguistic, cultural, and religious boundaries – emphasized the importance of establishing common ground and fostering a sense of belonging. The consequences of prioritizing efficiency and not cultivating a cohesive organisational culture during the integration of acquired enterprises has become increasingly apparent. Some companies find themselves with fragmented cultures, marked by low solidarity and disagreements about organisational objectives. This cultural deficit makes organisations challenging to manage, and leaders often feel powerless to effect change. In the MedTech sector, where collaboration and creativity are important for healthcare breakthroughs, cultural dissonance poses a significant risk. A robust and distinctive culture, however, is instrumental in attracting and retaining top talent, which is essential for success in an innovation-driven industry. A MedTech with a clear and supportive culture is better equipped to navigate industry intricacies, respond to emerging healthcare needs, and drive sustainable value creation.
 
This Commentary suggests that culture is community: a network of shared interests and obligations that thrive on cooperation and friendships. Acknowledging the heterogeneity within organisations is crucial, recognizing differences across departments and hierarchical levels. While financial and organisational considerations are critical, an approach encouraging a distinctive organisational culture is equally important. Neglecting cultural integration poses a silent yet substantial obstacle to growth and value creation - a challenge manifested through disengaged employees, talent attrition, and a lack of agility in meeting industry demands. Recognizing and redressing this cultural deficit transcends employee satisfaction; it emerges as a strategic imperative for long-term success in the dynamic landscape of MedTechs. As MedTech companies expand globally, the challenges to unite and motivate constituencies intensify. We have suggested that within this interconnected ecosystem, a unifying and motivating narrative emerges as a potential solution. A well-crafted story has the power to bridge gaps, align interests, and cultivate a shared sense of purpose among employees and stakeholders alike, contributing to a company’s success. The influence of a unifying narrative extends beyond an organisation's boundaries, serving as an inspiration for collective action. This shared story fuels innovation, enhances problem-solving, and transforms an organisation into a responsive and adaptable entity. In a world where trust, differentiation, innovation, talent attraction, stakeholder engagement, and customer loyalty are important, a captivating narrative becomes a positive contribution to the success of a diversified MedTech company. In the grand scheme of human endeavours, the power of stories seems undeniable. Whether in religion, politics, finance, or the women's movement, it is through stories that movements are built and legacies are shaped. Thus, for MedTechs to overcome the silent obstacle to growth and value creation, they might consider harnessing the power of narratives to fortify their brand identities, nurture relationships, and fuel long-term commercial success.
view in full page
load more Loading..